var title_f26_14_26848="Cerebral gumma";
var content_f26_14_26848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F64262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F64262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cerebral gumma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cerebral gumma in an HIV-infected patient with recent secondary syphilis. A) Coronal contrast enhanced T-1 weighted image shows focal meningeal enhancement in the left frontal lobe with surrounding edema. B) Axial FLAIR image shows significant edema in the left posterior frontal lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Christina M. Marra, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_14_26848=[""].join("\n");
var outline_f26_14_26848=null;
var title_f26_14_26849="NFL touchdown sign";
var content_f26_14_26849=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Overhead arm raise (or \"touchdown\" sign)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This maneuver screens overall shoulder range of motion and the strength of abduction. The patient is asked to raise both arms directly overhead. The smoothness of movement, degree of discomfort, and the ability to complete the maneuver are compared side to side. Similarly, the ability to smoothly control lowering the arm is compared side to side (the latter maneuver is analagous to the \"drop-arm\" sign).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_14_26849=[""].join("\n");
var outline_f26_14_26849=null;
var title_f26_14_26850="Patient information: Pelvic inflammatory disease (The Basics)";
var content_f26_14_26850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17117\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/52/23362\">",
"         Patient information: Chlamydia and gonorrhea (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/23/42353\">",
"         Patient information: Chronic pelvic pain in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/57/1940\">",
"         Patient information: Screening for sexually transmitted diseases (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/14/24802\">",
"         Patient information: Chlamydia (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/55/32627\">",
"         Patient information: Chronic pelvic pain in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/44/1730\">",
"         Patient information: Gonorrhea (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pelvic inflammatory disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/pelvic-inflammatory-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H5948397\">",
"      <span class=\"h1\">",
"       What is pelvic inflammatory disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Pelvic inflammatory disease, also called &ldquo;PID,&rdquo; is an infection that affects a woman&rsquo;s reproductive system (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ). In a woman, the reproductive system includes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The uterus (or womb), the organ that holds a baby when a woman is pregnant",
"       </li>",
"       <li>",
"        The ovaries, the organs that release eggs",
"       </li>",
"       <li>",
"        The fallopian tubes, which connect the ovaries to the uterus",
"       </li>",
"       <li>",
"        The vagina, which connects the uterus to the outside of the body",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      PID is caused by an infection you catch during sex. Chlamydia and gonorrhea are two of the most common infections that lead to PID. PID can cause ongoing (also called &ldquo;chronic&rdquo;) pain. It can also leave you unable to have a baby, because PID can cause scars to form on the fallopian tubes.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5948412\">",
"      <span class=\"h1\">",
"       What are the symptoms of PID?",
"      </span>",
"      &nbsp;&mdash;&nbsp;PID does not always cause symptoms. When it does, the main symptom is pain in the lower belly. In some women, this pain gets worse during sex.",
"     </p>",
"     <p>",
"      Other symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Chills",
"       </li>",
"       <li>",
"        Fluid leaking from the vagina (called &ldquo;discharge&rdquo;)",
"       </li>",
"       <li>",
"        Bleeding or spotting from the vagina",
"       </li>",
"       <li>",
"        Pain during a pelvic exam",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5948426\">",
"      <span class=\"h1\">",
"       Is there a test for PID?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no simple test that can show whether or not you have PID. But there are a few tests that can help your doctor or nurse find the possible cause of your problem.",
"     </p>",
"     <p>",
"      First, your doctor or nurse will do a pelvic exam to check for signs of infection or inflammation. Then, he or she might test your urine, blood, or vaginal discharge for signs of infection or other problems. He or she might also check a sample of your bowel movements to see if there&rsquo;s blood in it.",
"     </p>",
"     <p>",
"      Depending on your situation, you might also have other tests, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An ultrasound &ndash; This is an imaging test that creates pictures of the inside of your body. It is painless.",
"       </li>",
"       <li>",
"        A laparoscopy &ndash; During this procedure, a doctor inserts a thin tube called a &ldquo;laparoscope&rdquo; into your belly. The laparoscope has a camera and tools on the end. The doctor will use these tools to take samples of tissue.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5948441\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes! If you think you might have PID, it is very important find out and to start treatment right away. The longer you wait to get treated, the more likely you are to develop long-term problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5948458\">",
"      <span class=\"h1\">",
"       How is PID treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;PID is treated with antibiotics. These antibiotics come in different forms, and not everyone takes them in the same way. Some people take pills. Some people get a shot plus pills. And some people need to get the antibiotics in the hospital through an &ldquo;IV&rdquo; first and then take pills when they go home. Your doctor will decide which treatment is best for you.",
"     </p>",
"     <p>",
"      It is very important to take all the pills in your prescription, even if you feel better before you finish them. If you don&rsquo;t take all the pills, the infection could come back.",
"     </p>",
"     <p>",
"      If you have PID, your recent sex partners also need to see a doctor and get treatment. This includes anyone you had sex with in the 2 months before your symptoms started. If your sex partners are not treated, they can infect you again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5948473\">",
"      <span class=\"h1\">",
"       Can PID be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Since PID is caused by a germ that you get during sex, you can lower your risk of getting PID by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Using a latex condom every time you have sex",
"       </li>",
"       <li>",
"        Not having sex with a partner who has symptoms of an infection",
"       </li>",
"       <li>",
"        Not having sex at all",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5948490\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have had",
"      <strong>",
"      </strong>",
"      PID, you could have a hard time getting pregnant. That&rsquo;s because PID can cause scars to form on the fallopian tubes. If you do get pregnant, you will also have a higher-than-average chance of having an ectopic pregnancy, which can be dangerous. An ectopic pregnancy is when a baby starts to form in the fallopian tube, which then can burst.",
"     </p>",
"     <p>",
"      If you are trying to get pregnant, be sure to tell your doctor or nurse that you have had PID.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5948507\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/23/42353?source=see_link\">",
"       Patient information: Chronic pelvic pain in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=see_link\">",
"       Patient information: Chlamydia and gonorrhea (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=see_link\">",
"       Patient information: Screening for sexually transmitted diseases (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=see_link\">",
"       Patient information: Chlamydia (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=see_link\">",
"       Patient information: Gonorrhea (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32627?source=see_link\">",
"       Patient information: Chronic pelvic pain in women (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/14/26850?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17117 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-562547D45F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_14_26850=[""].join("\n");
var outline_f26_14_26850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5948397\">",
"      What is pelvic inflammatory disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5948412\">",
"      What are the symptoms of PID?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5948426\">",
"      Is there a test for PID?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5948441\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5948458\">",
"      How is PID treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5948473\">",
"      Can PID be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5948490\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5948507\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17117\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=related_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=related_link\">",
"      Patient information: Chlamydia and gonorrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32627?source=related_link\">",
"      Patient information: Chronic pelvic pain in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/23/42353?source=related_link\">",
"      Patient information: Chronic pelvic pain in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=related_link\">",
"      Patient information: Gonorrhea (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=related_link\">",
"      Patient information: Screening for sexually transmitted diseases (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_14_26851="Strontium-89: Drug information";
var content_f26_14_26851=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Strontium-89: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/55/27507?source=see_link\">",
"    see \"Strontium-89: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Metastron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F223325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Metastron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F223333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F223326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Measure dose by a suitable radioactivity calibration system immediately prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bone pain due to skeletal metastases:",
"     </b>",
"     I.V.: 148 megabecquerel (4 millicurie)",
"     <b>",
"      or",
"     </b>",
"     1.5-2.2 megabecquerel (40-60 microcurie)/kg; repeat doses are generally not recommended at intervals &lt;90 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F223327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F223315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as chloride [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metastron&reg;: 1 mCi/mL (4 mL) [37 megabecquerel per mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F223304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13164102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer intravenously slowly over 1-2 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F223316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of bone pain in patients with skeletal metastases",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15245851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F223331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing (after rapid injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills (case report), fever (case report)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia, thrombocytopenia (nadir: 12-16 weeks; recovery: 6 months)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain (transient increase; duration: 36-72 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Septicemia (case report)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F223318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F223307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radiopharmaceutical: Handle with caution, in a similar manner to other radioactive drugs; appropriate safety measures to minimize radiation to personnel should be instituted. Body fluids may remain radioactive up to 1 week after injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Marrow toxicity (thrombocytopenia and leukopenia) is likely to occur. Use is not recommended in patients with seriously compromised bone marrow function from prior therapies or from disease infiltration (unless potential benefit outweighs risks). Monitor CBC weekly. Use with caution in patients whose platelet counts fall &lt;60,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or whose white blood cell counts fall &lt;2400/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Carefully evaluate bone marrow status and toxicity of initial treatment if considering repeat administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone pain: A small number of patients have experienced a transient increase in bone pain at 36-72 hours postdose; this reaction is generally mild and self-limiting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Flushing: Patients may experience a flushing sensation following rapid (&lt;30 seconds) injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Incontinence: Incontinent patients may require urinary catheterization (to minimize radioactive contamination).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Primarily eliminated renally; possible risk versus benefit  should be evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not indicated for use in patients with cancer not involving bone or in patients with a short life expectancy (due to delayed onset of pain relief).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced staff: Should only be used under the supervision of nuclear medicine physicians and/or radiopharmacists qualified and experienced in use and handling of radionuclides.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F223311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13164080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause fetal harm if administered during pregnancy. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should avoid becoming pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13164081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion is breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Metastron Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mci/mL (4 mL): $6195.94",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F223313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (every other week)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F223321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Metastron (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13164519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selectively (locally) irradiates primary and metastatic bone lesions to reduce pain.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13164098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: Pain relief: 7-20 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Retained in bone mineral (preferentially to metastatic bone lesions)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: In patients with bone metastases: Urine (67%); feces (33%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Robinson RG, Preston DF, Schiefelbein M, et al, &ldquo;Strontium 89 Therapy for the Palliation of Pain Due to Osseous Metastases,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1995, 274(5):420-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/14/26851/abstract-text/7542352/pubmed\" id=\"7542352\" target=\"_blank\">",
"        7542352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silberstein EB, Buscombe JR, McEwan A, et al, &ldquo;Clinical Guidelines: Society of Nuclear Medicine Procedure Guideline for Palliative Treatment of Painful Bone Metastases 3.0,&rdquo; 2003. Available at file://interactive.snm.org/docs/pg_ch25_0403.pdf. Last accessed May 13, 2010.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9950 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_14_26851=[""].join("\n");
var outline_f26_14_26851=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223324\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223325\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223333\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223326\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223327\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223315\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223304\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13164102\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223316\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245851\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223331\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223318\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223307\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300084\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223106\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223311\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13164080\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13164081\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323894\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223313\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223321\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13164519\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13164098\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9950\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9950|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/55/27507?source=related_link\">",
"      Strontium-89: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_14_26852="Scrub typhus: Treatment and prevention";
var content_f26_14_26852=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Scrub typhus: Treatment and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/14/26852/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/14/26852/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/14/26852/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/14/26852/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/14/26852/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/14/26852/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/14/26852/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scrub typhus is a mite-borne infectious disease caused by Orientia tsutsugamushi (previously called Rickettsia tsutsugamushi). It is distributed throughout the Asia Pacific rim, being endemic in Korea, China, Taiwan, Japan, Pakistan, India, Thailand, Malaysia, and northern portions of Australia. However, cases also occur in the United States, Canada, and Europe, being imported by tourists returning from endemic regions.",
"   </p>",
"   <p>",
"    Scrub typhus is manifested clinically by high fever, intense generalized headache, diffuse myalgias, and, in many patients, rash and an eschar at the site of the chigger bite. The diagnosis is suggested by the clinical history (including visit to an endemic area) and physical findings and confirmed by serologic testing or biopsy of an eschar. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18534?source=see_link\">",
"     \"Scrub typhus: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scrub typhus lasts for 14 to 21 days without treatment. Severe infections may be complicated by interstitial pneumonia, pulmonary edema, congestive heart failure, circulatory collapse, and a wide array of signs and symptoms of central nervous system dysfunction, including delirium, confusion, and seizures. Death may occur as a result of these complications, usually late in the second week of the illness.",
"   </p>",
"   <p>",
"    By contrast, patients treated with appropriate antibiotics typically become afebrile within 48 hours of starting therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/1\">",
"     1",
"    </a>",
"    ]. This response to treatment may be useful diagnostically; failure of defervescence within 48 hours is often considered evidence that scrub typhus is not present, and that an alternate diagnosis such as malaria or dengue should be considered. However, in a 2004 report, 20 of 93 patients with serologically confirmed scrub typhus had a delay in defervescence to more than 48 hours, making the reliability of this long-standing clinical truism suspect [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/2\">",
"     2",
"    </a>",
"    ]. The authors of another report retrospectively examined the clinical characteristics of 18 patients with Q fever (9), scrub typhus (7) or murine typhus (2) who failed to respond within 48 hours to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and compared their clinical features to 88 cases who responded promptly. Delayed defervescence was associated with jaundice and relative bradycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     Chloramphenicol",
"    </a>",
"    was the first drug shown to be effective in the treatment of scrub typhus, and is still commonly used in endemic regions. Doses of 250 to 500 mg orally or intravenously every six hours are effective. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg orally or intravenously twice daily) is now the drug of choice for this illness.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    has been advocated as an alternative agent in special circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An analysis of all treatment trials for scrub typhus published prior to 2000 concluded that only three trials comparing the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    were adequately designed to assess the two most relevant outcomes: time to resolution of fever and incidence of relapse. These three studies found no significant differences in outcomes in patients treated with doxycycline and those patients treated with chloramphenicol [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/4\">",
"     4",
"    </a>",
"    ]. However, these studies were performed before the recognition that some strains of O. tsutsugamushi have reduced susceptibility to tetracyclines. Also, these studies did not examine the potentially important relationship between delays in treatment and outcome. In a retrospective review of 92 cases of severe rickettsial infection (that included 34 cases of proven scrub typhus), delayed administration of doxycycline was independently associated with the development of major organ dysfunction (OR 1.2; CI 1.0-1.5) and hospitalization &gt;10 days (OR 1.4; CI 1.1-1.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are some preliminary in vitro and clinical data on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    for the treatment of scrub typhus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/6\">",
"     6",
"    </a>",
"    ]. A randomized open-label treatment trial in South Korea (an area where strains of O. tsutsugamushi that have reduced susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    is thought to be uncommon) compared azithromycin with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    for mild disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/2\">",
"     2",
"    </a>",
"    ]. Ninety-three patients were assigned to receive a single 500 mg dose of azithromycin or seven days of doxycycline (200 mg daily). Both antibiotic regimens were clinically effective in reducing days with fever. No relapses were observed in either group at one-month follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of therapy is uncertain. Regimens as short as one day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (400 mg given in two divided doses) have been advocated for the therapy of scrub typhus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/7\">",
"     7",
"    </a>",
"    ]. However, it has been suggested that short courses of doxycycline or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    are associated with an increased risk of relapse. An early study of three-day therapy found that relapse occurred in three of seven patients treated with chloramphenicol and three of six treated with doxycycline; in comparison, no relapses were noted in 37 patients treated with either regimen for five days or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a larger, more recent study found short course therapy to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/8\">",
"     8",
"    </a>",
"    ]. In this multicenter trial, 116 patients with scrub typhus were randomized to receive seven days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (500 mg four times daily) or three days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg twice daily). The patients were followed for four weeks after the completion of therapy. The cure rate was 100 percent in the tetracycline group, and 94 percent in the doxycycline group. There were no relapses with either regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scrub typhus may cause spontaneous abortions in pregnant women. Some authorities advocate use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    in pregnant women for its safety profile and in vitro efficacy. A recent report described the outcomes of eight pregnant women infected with O. tsutsugamushi who were treated with a single 500 mg dose of azithromycin. All recovered fully and delivered healthy infants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Strains with reduced susceptibility to tetracycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some strains of O. tsutsugamushi are resistant or unresponsive to therapy with tetracyclines (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ). Some experts have proposed the use of alternative drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or combination therapy including a rifamycin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Azithromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authorities believe",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    may be a suitable alternative treatment for patients with refractory disease from locations where",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    -resistant strains of O. tsutsugamushi have been found [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/6\">",
"     6",
"    </a>",
"    ]. Encouraging results were noted in an open label study that compared the efficacy of a seven-day course of doxycycline with a three-day course of azithromycin in 57 Thai patients with proven scrub typhus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/10\">",
"     10",
"    </a>",
"    ]. Treatment failure occurred in one patient receiving azithromycin and in none of the patients receiving doxycycline [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second randomized trial performed in an area of northern Thailand (where strains of O. tsutsugamushi with reduced susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    are prevalent), compared the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    alone to the combination of doxycycline and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    in 86 patients with mild scrub typhus infection. The median duration of fever was significantly shorter in the 24 patients treated with daily doses of 900 and 600 mg of rifampin (mean fever clearance times 22.5 and 27.5 hours, respectively) than in 52 patients treated with doxycycline therapy alone (mean fever clearance time 52 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No vaccine is available to prevent the transmission of scrub typhus. Furthermore, the antigenic heterogeneity of O. tsutsugamushi suggests that the prospect of future vaccine development will be a difficult undertaking [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/12\">",
"     12",
"    </a>",
"    ]. Thus, current attempts at prevention consist of chemoprophylaxis and mite control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chemoprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have demonstrated that chemoprophylaxis with a long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    is highly effective when used by non-immune individuals living or working in areas in which scrub typhus is endemic. In one report, for example, clinical disease occurred in only 1 of 10 individuals treated with a weekly 200 mg dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , despite exposure to an environment in which chiggers infected with O. tsutsugamushi were prevalent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26852/abstract/13\">",
"     13",
"    </a>",
"    ]. All of the patients developed antibodies to scrub typhus. In contrast, clinical disease occurred in 9 of 10 control subjects who were simultaneously exposed to the same environment, but did not take chemoprophylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mite control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of insect repellants and miticides such as N,N-diethyl-3-methylbenzamide (DEET) are highly effective when applied to both clothing and skin.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     Permethrin",
"    </a>",
"    and benzyl benzoate are also useful agents when applied to clothing and bedding. Focal areas such as military camps or specialized work areas can be treated with chlorinated hydrocarbons such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"     lindane",
"    </a>",
"    , dieldrin, or chlordane. These chemicals are highly effective against trombiculid mites, although they may cause secondary environmental problems.",
"   </p>",
"   <p>",
"    Intensive efforts at rodent control may paradoxically increase the risk of human disease. In this setting, chiggers lose their preferred and normal hosts, thereby becoming more likely to bite humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8093085\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scrub typhus is a mite-borne infectious disease caused by Orientia tsutsugamushi, which is distributed throughout Asia and northern portions of Australia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"       chloramphenicol",
"      </a>",
"      are comparable in shortening clinical illness and the incidence of relapse of infection. However, chloramphenicol is associated with significant drug toxicity, such as bone marrow suppression. We suggest doxycycline for treatment of scrub typhus. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Scrub typhus may cause spontaneous abortions in pregnant women.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       Azithromycin",
"      </a>",
"      is an alternative drug to treat scrub typhus, which has an acceptable safety profile in pregnant women. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several studies have demonstrated that chemoprophylaxis with a long-acting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      is highly effective when used by nonimmune individuals living or working in areas in which scrub typhus is endemic. The use of insect repellants and miticides are highly effective when applied to both clothing and skin.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"       Permethrin",
"      </a>",
"      and benzyl benzoate are also useful agents when applied to clothing and bedding. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26852/abstract/1\">",
"      Sheehy TW, Hazlett D, Turk RE. Scrub typhus. A comparison of chloramphenicol and tetracycline in its treatment. Arch Intern Med 1973; 132:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26852/abstract/2\">",
"      Kim YS, Yun HJ, Shim SK, et al. A comparative trial of a single dose of azithromycin versus doxycycline for the treatment of mild scrub typhus. Clin Infect Dis 2004; 39:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26852/abstract/3\">",
"      Lai CH, Huang CK, Weng HC, et al. Clinical characteristics of acute Q fever, scrub typhus, and murine typhus with delayed defervescence despite doxycycline treatment. Am J Trop Med Hyg 2008; 79:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26852/abstract/4\">",
"      Panpanich R, Garner P. Antibiotics for treating scrub typhus. Cochrane Database Syst Rev 2000; :CD002150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26852/abstract/5\">",
"      Lee N, Ip M, Wong B, et al. Risk factors associated with life-threatening rickettsial infections. Am J Trop Med Hyg 2008; 78:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26852/abstract/6\">",
"      Strickman D, Sheer T, Salata K, et al. In vitro effectiveness of azithromycin against doxycycline-resistant and -susceptible strains of Rickettsia tsutsugamushi, etiologic agent of scrub typhus. Antimicrob Agents Chemother 1995; 39:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26852/abstract/7\">",
"      Brown GW, Saunders JP, Singh S, et al. Single dose doxycycline therapy for scrub typhus. Trans R Soc Trop Med Hyg 1978; 72:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26852/abstract/8\">",
"      Song JH, Lee C, Chang WH, et al. Short-course doxycycline treatment versus conventional tetracycline therapy for scrub typhus: a multicenter randomized trial. Clin Infect Dis 1995; 21:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26852/abstract/9\">",
"      Kim YS, Lee HJ, Chang M, et al. Scrub typhus during pregnancy and its treatment: a case series and review of the literature. Am J Trop Med Hyg 2006; 75:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26852/abstract/10\">",
"      Phimda K, Hoontrakul S, Suttinont C, et al. Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus. Antimicrob Agents Chemother 2007; 51:3259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26852/abstract/11\">",
"      Watt G, Kantipong P, Jongsakul K, et al. Doxycycline and rifampicin for mild scrub-typhus infections in northern Thailand: a randomised trial. Lancet 2000; 356:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26852/abstract/12\">",
"      Chattopadhyay S, Richards AL. Scrub typhus vaccines: past history and recent developments. Hum Vaccin 2007; 3:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26852/abstract/13\">",
"      ANDREW R, BONNIN JM, WILLIAMS S. Tick typhus in North Queensland. Med J Aust 1946; 2:253.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7911 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_14_26852=[""].join("\n");
var outline_f26_14_26852=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8093085\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Strains with reduced susceptibility to tetracycline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Azithromycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mite control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8093085\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18534?source=related_link\">",
"      Scrub typhus: Clinical features and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_14_26853="Clomipramine: Patient drug information";
var content_f26_14_26853=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Clomipramine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     see \"Clomipramine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/37/11864?source=see_link\">",
"     see \"Clomipramine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F153279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anafranil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F153280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Anafranil&reg;;",
"     </li>",
"     <li>",
"      Apo-Clomipramine&reg;;",
"     </li>",
"     <li>",
"      CO Clomipramine;",
"     </li>",
"     <li>",
"      Dom-Clomipramine;",
"     </li>",
"     <li>",
"      Novo-Clomipramine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691994",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat obsessive-compulsive problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat panic attacks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701838",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to clomipramine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703749",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a recent heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4232023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any of these drugs: Linezolid or methylene blue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695854",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime if it causes sleepiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12278 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-E5FD8A8851-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_14_26853=[""].join("\n");
var outline_f26_14_26853=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153279\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153280\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011253\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011255\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011254\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011259\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011260\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011262\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011257\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011258\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011263\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011264\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=related_link\">",
"      Clomipramine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/37/11864?source=related_link\">",
"      Clomipramine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_14_26854="Chlorthalidone: Drug information";
var content_f26_14_26854=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorthalidone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/21/8533?source=see_link\">",
"    see \"Chlorthalidone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/46/35557?source=see_link\">",
"    see \"Chlorthalidone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Thalitone&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F150696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Chlorthalidone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F150714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F150699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edema: Initial: 50-100 mg once daily or 100 mg on alternate days; maximum dose: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heart failure-associated edema: Initial: 12.5-25 mg once daily; maximum dose: 100 mg/day (ACC/AHA 2009 Heart Failure Guidelines)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypertension: Oral: Initial: 25 mg once daily; may increase after a suitable trial to 50 mg once daily; maximum: 100 mg/day; usual dosage range (JNC 7): 12.5-25 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F150709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/46/35557?source=see_link\">",
"      see \"Chlorthalidone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension (unlabeled use):",
"     </b>",
"     Children and Adolescents: Oral: Initial: 0.3 mg/kg once daily, up to 2 mg/kg/day; maximum: 50 mg/day (NHBPEP, 2004; NHLBI, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F150700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial: 12.5-25 mg once daily or every other day; there is little advantage to using doses &gt;25 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F150701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;10 mL/minute: No dosage adjustment necessary (Aronoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use. Ineffective with low GFR (Aronoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     ACC/AHA 2009 Heart Failure Guidelines suggest that thiazides lose their efficacy when Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thalitone&reg;: 15 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F150678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of mild-to-moderate hypertension when used alone or in combination with other agents; treatment of edema associated with heart failure, renal dysfunction, hepatic cirrhosis, or corticosteroid and estrogen therapy.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F4589531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pediatric hypertension",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F150712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, dyspepsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, aplastic anemia, cholecystitis, diabetes mellitus, gout, hypercalcemia, hyperglycemia, hypersensitivity reactions, hypochloremic alkalosis, hyponatremia, leukopenia, necrotizing angiitis, orthostatic hypotension, pancreatitis, renal impairment, thrombocytopenia, toxic epidermal necrolysis, vasculitis, xanthopsia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F150681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorthalidone, other sulfonamide-derived drugs, or any component of the formulation; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F150663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hypokalemia, hypochloremic alkalosis, and hyponatremia can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with thiazide or sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with a history of bronchial asthma; hypersensitivity reactions may occur more readily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with hypokalemia; correct before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Avoid in severe renal disease (ineffective).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Can cause SLE exacerbation or activation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F150691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid herbs with",
"     <i>",
"      hypertensive",
"     </i>",
"     properties (bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng [American], kola, licorice); may diminish the antihypertensive effect of chlorthalidone. Avoid herbs with",
"     <i>",
"      hypotensive",
"     </i>",
"     properties (black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse); may enhance the hypotensive effect of chlorthalidone.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F150670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10923684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Chlorthalidone crosses the placenta and can be detected in cord blood and amniotic fluid. Maternal use may cause may cause fetal or neonatal jaundice, thrombocytopenia, or other adverse events observed in adults. Use of thiazide diuretics during normal pregnancies is not appropriate; use may be considered when edema is due to pathologic causes (as in the nonpregnant patient); monitor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F150704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F150684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This product may cause a potassium loss; your healthcare provider may prescribe a potassium supplement, another medication to help prevent the potassium loss, or recommend that you eat foods high in potassium, especially citrus fruits; do not change your diet on your own while taking this medication, especially if you are taking potassium supplements or medications to reduce potassium loss; too much potassium can be as harmful as too little.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F150683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Chlorthalidone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $55.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $68.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $101.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F150673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Assess weight, I &amp; O records daily to determine fluid loss; blood pressure, serum electrolytes, renal function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F150685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aquadon (IL);",
"     </li>",
"     <li>",
"      Clortalil (BR);",
"     </li>",
"     <li>",
"      Higroton (BR, MX, VE);",
"     </li>",
"     <li>",
"      Higrotona (ES);",
"     </li>",
"     <li>",
"      Hygroton (AE, AR, AT, AU, BB, BE, BF, BH, BJ, BM, BS, BZ, CH, CI, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HN, ID, IE, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PL, PT, PY, QA, RU, SA, SC, SD, SE, SK, SL, SN, SR, SY, TN, TR, TT, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Hythalton (IN);",
"     </li>",
"     <li>",
"      Igroton (IT);",
"     </li>",
"     <li>",
"      Saluretin (BG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F150662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sulfonamide-derived diuretic that inhibits sodium and chloride reabsorption in the cortical-diluting segment of the ascending loop of Henle",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F150680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 24-72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 40-60 hours; may be prolonged with renal impairment; Anuria: 81 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~50% to 65% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, \"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(23):2981-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/14/26854/abstract-text/12479763/pubmed\" id=\"12479763\" target=\"_blank\">",
"        12479763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/14/26854/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007, 43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, \"ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/14/26854/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/14/26854/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/14/26854/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liebson PR, Grandits GA, Dianzumba S, et al, &ldquo;Comparison of Five Antihypertensive Monotherapies and Placebo for Change in Left Ventricular Mass in Patients Receiving Nutritional-Hygienic Therapy in the Treatment of Mild Hypertension Study (TOMHS),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1995, 91(30):698-706.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/14/26854/abstract-text/7828296/pubmed\" id=\"7828296\" target=\"_blank\">",
"        7828296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/14/26854/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mulley BA, Parr GD, Pau WK, et al, \"Placental Transfer of Chlorthalidone and its Elimination in Maternal Milk,\"",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1978, 13(2):129-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/14/26854/abstract-text/658109/pubmed\" id=\"658109\" target=\"_blank\">",
"        658109",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute (NHLBI), \"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, Clinical Practice Guidelines, 2011,\" U.S. Department of Health and Human Services, National Institutes of Health. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf",
"      </a>",
"      . Accessed June 11, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (NHBPEP), &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/14/26854/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(24):3255-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/14/26854/abstract-text/2046107/pubmed\" id=\"2046107\" target=\"_blank\">",
"        2046107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Savage PJ, Pressel SL, Curb JD, et al, &ldquo;Influence of Long-Term, Low-Dose, Diuretic-Based, Antihypertensive Therapy on Glucose, Lipid, Uric Acid, and Potassium Levels in Older Men and Women With Isolated Systolic Hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(7):741-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/14/26854/abstract-text/9554680/pubmed\" id=\"9554680\" target=\"_blank\">",
"        9554680",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9255 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_14_26854=[""].join("\n");
var outline_f26_14_26854=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150695\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150696\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150714\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150699\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150709\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150700\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150701\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682603\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150675\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150659\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150678\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4589531\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150712\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150681\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150663\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299032\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150668\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150691\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150670\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10923684\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150704\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150684\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150683\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150673\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150685\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150662\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150680\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9255\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9255|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/21/8533?source=related_link\">",
"      Chlorthalidone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/46/35557?source=related_link\">",
"      Chlorthalidone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_14_26855="Rubella";
var content_f26_14_26855=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rubella",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/14/26855/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/14/26855/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/14/26855/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/14/26855/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/14/26855/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/14/26855/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/14/26855/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two German physicians, De Bergen and Orlow, are credited with the first description of rubella in the 1750s; the subsequent attention it received in the German literature led to its appellation \"German measles\" [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/1\">",
"     1",
"    </a>",
"    ]. Initially, rubella was thought to be a variant related to measles or scarlet fever and was called the \"Third Exanthematous Disease of Childhood\" or the \"three day measles\". In 1866, Veale, a Scottish physician serving as an English Royal Artillery surgeon, proposed changing the name to rubella, from the Latin \"little red\" [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The viral etiology of rubella was suspected by Hess in 1914 based on experiments of inoculating monkeys with blood obtained from children with acute manifestations of rubella [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/3\">",
"     3",
"    </a>",
"    ]. This was later confirmed by the transmission of filtered secretions from individuals with acute rubella to susceptible children by Hiro and Tosaka in 1938 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Australian ophthalmologist Norman McAlister Gregg first made the seminal observation of the teratogenic effects of rubella in 1941 by describing the association of congenital cataracts with maternal rubella [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/5\">",
"     5",
"    </a>",
"    ]. Subsequently, rubella infection during early gestation was associated with the devastating array of congenital defects comprising the \"Congenital Rubella Syndrome\" (CRS). This led to the development of live-attenuated rubella vaccines.",
"   </p>",
"   <p>",
"    In countries employing mass immunization campaigns and recommendations for universal immunization of children, rubella cases and congenital rubella cases declined precipitously. In regions of the developing world lacking rubella immunization programs, a high proportion of women of childbearing age remain susceptible to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/6-11\">",
"     6-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microbiology, epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment and prevention of rubella will be reviewed here. Issues related to rubella in pregnancy and congenital rubella syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6087?source=see_link\">",
"     \"Rubella in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=see_link\">",
"     \"Congenital rubella syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36855?source=see_link\">",
"     \"Congenital rubella syndrome: Management, outcome, and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rubella virus is a member of the Togavirus family, which includes two genera of small enveloped RNA viruses: Alphavirus and Rubivirus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The family name Togavirus comes from \"toga\" or \"ring\", since electron microscopy demonstrates a characteristic lucent ring between the nucleocapsid core and envelope.",
"   </p>",
"   <p>",
"    Rubella virus is the only member of the Rubivirus genus. Its genomic structure and replication process are similar to those of the alphaviruses. In contrast to the alphaviruses, however, humans are the only natural host, though experimental rubella virus infection may be induced in a range of vertebrate animals.",
"   </p>",
"   <p>",
"    Rubella virus's positive-sense, single-stranded RNA encodes three structural proteins: C, E1, and E2 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/12\">",
"     12",
"    </a>",
"    ]. These proteins are encoded as a single precursor on a 24S subgenomic mRNA and cleaved by cellular peptidases. The capsid protein, C, surrounds the RNA of the virion while the glycosylated proteins, E1 and E2, form transmembrane spikes and serve as the major antigenic sites of the virus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/12,14\">",
"     12,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attachment of the virus occurs at the cell surface, and cell entry likely occurs by transportation into endosomes mediated by specific cellular receptors. The cellular receptor for rubella virus has not yet been elucidated, but the virus's wide tissue tropism suggests membrane phospholipids and glycolipids may be important [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Viral replication takes place in the cytoplasm of the host cell. Virus particles assemble on intracellular membranes. The mechanism of virus release from cells remains undefined, but the cytoplasmic domain of E1 is required [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/12,14\">",
"     12,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rubella virus can be grown in many primary and continuous cell lines derived from human, non-human primate, and other vertebrate tissue. Induction of apoptosis appears to be the primary mechanism by which cytopathic effect (CPE) is produced [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/14\">",
"     14",
"    </a>",
"    ]. However, identification and quantification of rubella virus in these cell lines are commonly problematic because the CPE is often minimal and variable. Identification is more reliably accomplished by antigenic and molecular assays, such as immunofluorescence and the polymerase chain reaction (PCR). Rubella virus's replication in tissue culture also may be detected by its ability to interfere with the replication of another virus for which the cell line is sensitive (ie, interference).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND VACCINE DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the development and introduction of rubella vaccine, outbreaks of rubella occurred variably every few years, peaking in the winter and early spring in temperate areas. The incidence tended to be highest among school-age children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1962, rubella virus was first isolated in cell culture, allowing for the development of attenuated strains for candidate vaccines. Three live-attenuated vaccines were licensed in the United States in 1969 to 1970: HPV-77 grown in duck embryo cells, HPV-77 grown in dog kidney cells, and Cendehill vaccine grown in rabbit kidney cells. Use of these vaccines resulted in a precipitous fall in the number of reported rubella cases.",
"   </p>",
"   <p>",
"    The RA",
"    <span class=\"nowrap\">",
"     27/3",
"    </span>",
"    vaccine, grown in human diploid fibroblasts, was licensed in Europe in 1971-1972. The RA",
"    <span class=\"nowrap\">",
"     27/3",
"    </span>",
"    vaccine provides better individual protection, herd immunity, and fewer adverse joint manifestations. Thus, RA",
"    <span class=\"nowrap\">",
"     27/3",
"    </span>",
"    became the single vaccine licensed in the United States in 1979 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/13,15\">",
"     13,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accurate estimates of the number of cases of rubella in the United States were not possible until rubella and congenital rubella syndrome became nationally notifiable diseases in 1966 (",
"    <a class=\"graphic graphic_figure graphicRef70446 \" href=\"UTD.htm?17/22/17775\">",
"     figure 1",
"    </a>",
"    ). In 1964-1965, over 12 million cases of rubella and 20,000 cases of congenital rubella syndrome (CRS) were recorded. In 1969, just before the introduction of the vaccine, the reported incidence of rubella was 58 cases per 100,000 population. By 1983, fewer than 0.5 cases per 100,000 population were reported. Resurgence of rubella occurred during 1990 and 1991 due to outbreaks in California and Pennsylvania. The lowest number of cases reported annually was seven, in 2003. In 2004, rubella was officially declared eliminated from the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/16\">",
"     16",
"    </a>",
"    ]. In 2010, rubella was declared eliminated from the Americas [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Global occurrence of rubella",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of rubella vaccine generally correlates with a country's economic development. At the end of 2002, rubella immunization existed in 100 percent of industrialized nations, in 71 percent of countries with economies in transition, and in 48 percent of developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2006, 123 (58 percent) of 212 countries and territories had national immunization programs for rubella [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/14,18\">",
"     14,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period of rubella is usually 14 to 18 days (range 12 to 23 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/16,19,20\">",
"     16,19,20",
"    </a>",
"    ]. Rubella is acquired via inhalation of infectious large particle aerosols and thus is augmented by close and prolonged contact with infected individuals. Initial replication occurs in nasopharyngeal cells and regional lymph nodes. Viremia occurs five to seven days after inoculation, allowing the virus to spread throughout the body. The virus can be isolated from the pharynx and blood during this period and on occasion may be isolated subsequently from a number of other sites including synovial fluid, urine, bronchoalveolar lavage fluid, and cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infected individuals may shed virus and are potentially contagious for one to two weeks before the infection becomes clinically apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/21\">",
"     21",
"    </a>",
"    ]. In many cases, rubella infection is asymptomatic, and the shedding and infectiousness of the infected individual is never recognized. With the appearance of the rash, typically 14 to 17 days after exposure, viral shedding decreases concurrent with the development of neutralizing antibodies. Therefore, the rash has been postulated as being immune-mediated.",
"   </p>",
"   <p>",
"    IgG antibodies produced after rubella infection provide protective immunity, but reinfection can occur. Re-exposure can produce a significant rise in the pre-existing titer, but rarely results in detectable viremia or risk to a developing fetus. A few cases of fetal infection following maternal reinfection have been reported, however [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of postnatally acquired rubella are generally mild, and many cases are subclinical or asymptomatic. Illness among children tends to be milder than illness among adults, with fewer prodromal symptoms and complications.",
"   </p>",
"   <p>",
"    The clinical manifestations of postnatal rubella infection among children typically include the acute onset of a maculopapular rash with minimal systemic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/13,14,19,21\">",
"     13,14,19,21",
"    </a>",
"    ]. Low grade fever and lymphadenopathy may occur concurrently or one to five days prior to the appearance of the exanthem. The lymphadenopathy characteristically involves the posterior cervical, posterior auricular, and suboccipital lymph nodes.",
"   </p>",
"   <p>",
"    The exanthem consists of pinpoint, pink maculopapules. The rash first appears on the face, spreads caudally to the trunk and extremities, and becomes generalized within 24 hours (",
"    <a class=\"graphic graphic_picture graphicRef61263 \" href=\"UTD.htm?10/17/10513\">",
"     picture 1",
"    </a>",
"    ). The rash usually is evident for about three days, but may last only one to two days or occasionally as long as eight days. Although the distribution of the rubella rash is similar to that of rubeola, the spread is much more rapid, and the rash does not darken or coalesce. Mild nonexudative conjunctivitis and an enanthem on the soft palate (Forchheimer spots) also may be observed, and occasionally acute thyroiditis develops.",
"   </p>",
"   <p>",
"    Primary infection among teenagers and adults tends to be of longer duration than that among young children. Patients are more frequently symptomatic, and symptoms are more frequently accompanied by a prodrome of fever and systemic complaints. The exanthem in adults is similar to that in children, as described above. Arthralgias and arthritis occur among as many as 70 percent of teenagers and adult women. Therefore, these findings are not considered complications, but rather part of the case definition in these groups [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/16\">",
"     16",
"    </a>",
"    ]. Among children and adult males, joint manifestations are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arthritis and arthralgias usually occur concurrently with the rash and may persist for a month or more. The knees, wrists, and fingers are most frequently involved. Although cases of chronic arthritis with rubella have been reported occasionally, the role of rubella virus in causing chronic forms of arthritis is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=see_link\">",
"     \"Specific viruses that cause arthritis\"",
"    </a>",
"    .) Additional findings may include conjunctivitis, testalgia, and orchitis.",
"   </p>",
"   <p>",
"    Complications of rubella are infrequent; they are observed more frequently among teenagers and adults than children. Postinfectious encephalitis occurs in about 1 per 6000 rubella cases, usually within a week of the exanthem, but may occur without any rash. The encephalitis may be immune-mediated. In general the prognosis is good, although fatal cases have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. Progressive rubella panencephalitis is a rare and devastating complication. Hemorrhagic complications are estimated to occur in approximately 1 per 3000 cases and more frequently among children than adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Congenital rubella syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent defect associated with congenital rubella syndrome is hearing loss, followed by mental retardation, cardiovascular defects, and ocular defects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=see_link\">",
"     \"Congenital rubella syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36855?source=see_link\">",
"     \"Congenital rubella syndrome: Management, outcome, and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of rubella includes infectious and noninfectious causes such as skin diseases and drug reactions. Infections that should be considered include scarlet fever and parvovirus infections since these are common infections with similar rashes. Parvovirus infection in adults also is similarly associated with arthritis and arthralgia. Roseola (human herpesviruses 6 and 7), rash-associated enteroviral infections, infectious mononucleosis, mild and vaccine-associated measles, and toxoplasmosis also may have similar rashes.",
"   </p>",
"   <p>",
"    Routine nonspecific laboratory tests are not specific or helpful in differentiating rubella from other diseases. Specific laboratory diagnosis is appropriate when:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital rubella syndrome is suspected",
"     </li>",
"     <li>",
"      Diagnosis is sought for a condition compatible with known complications of rubella, such as arthritis, hemorrhagic purpura, and central nervous system disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rubella infection is most commonly diagnosed by detection of rubella-specific IgM antibodies using an enzyme immunoassay (EIA) with commercially available kits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/14,27\">",
"     14,27",
"    </a>",
"    ]. The EIA capture assay provides greater specificity than the indirect EIA, which may give false positive results in the presence of rheumatoid factor and some viral infections such as parvovirus, Epstein-Barr virus, and cytomegalovirus.",
"   </p>",
"   <p>",
"    Specific IgM antibody can be detected as early as four days after the onset of rash and is usually detectable after primary infection for six to eight weeks or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/28\">",
"     28",
"    </a>",
"    ]. The positive predictive value of rubella IgM detection is particularly low in populations with high immunization rates and low prevalence of rubella virus. Rubella infection and reinfection can be demonstrated by a fourfold rise in rubella IgG antibody concentrations between acute and convalescent sera. Recent infection may also be detected by measurement of low avidity IgG rubella antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/14,29\">",
"     14,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Viral isolation from nasopharyngeal secretions can be used to confirm acute rubella infection during pregnancy. Congenital infection may be confirmed by viral isolation from the cord blood or placenta, as well as from nasopharyngeal secretions and urine of the newborn. Viral isolation, however, is rarely used or available because of its technical difficulty and expense. Reverse transcription polymerase chain reaction (RT-PCR) assays have been used to diagnose in utero rubella infection by detection of rubella RNA in amniotic fluid and other products of conception [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/12,14,30\">",
"     12,14,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=see_link&amp;anchor=H17#H17\">",
"     \"Congenital rubella syndrome: Clinical features and diagnosis\", section on 'Laboratory diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment consists of supportive care. No specific therapy for rubella infection is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of rubella vaccination is to prevent congenitally acquired rubella. Immunization of all young children is required to reduce rates of CRS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/13,26\">",
"     13,26",
"    </a>",
"    ]. Although live-attenuated rubella vaccines initially were shown to be effective in preventing rubella among adult women and prepubertal girls, immunization programs that selectively vaccinated these groups (as in the United Kingdom) failed to diminish the overall incidence of congenital rubella syndrome (CRS) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The currently available rubella vaccine is the",
"    <span class=\"nowrap\">",
"     RA/23",
"    </span>",
"    strain grown in human diploid cell cultures. At least one dose of live attenuated rubella containing vaccine is recommended for all individuals 12 months of age or older. The World Health Organization recommends that the measles, mumps, rubella vaccine (MMR) be first given at 12 to 18 months of age, with a second dose at 36 months. In the United States, the recommendations are for routine immunization with MMR or MMR combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    (MMRV) administered at 12 to 15 months of age, with a second dose of MMR at four to six years when entering school [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. If a child has not received the second dose at school entry, it should be administered as soon as possible, but no later than 11 to 12 years of age. Pregnant women should be tested early in pregnancy for rubella immunity. Susceptible women should receive immunization after the child is born. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H22#H22\">",
"     \"Standard immunizations for children and adolescents\", section on 'MMR vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One dose of vaccine produces a seroconversion rate of about 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/20\">",
"     20",
"    </a>",
"    ]. The durability of antibodies produced by the vaccine and by naturally acquired infection is comparable. Titers of antibody induced by vaccine tend to be lower than those produced by natural infection, but are protective against infection. Some individuals have been reported to experience symptomatic and asymptomatic infection despite previous immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Asymptomatic reinfection usually does not lead to detectable viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rubella vaccine is generally well tolerated. Among children receiving MMR or MMRV vaccines, fever develops 5 to 14 days after vaccination in 5 to 22 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Usually the fever is low grade, but febrile seizures may occur primarily among children 12 to 24 months of age. Fever and seizures are more common among those receiving an MMRV vaccine than MMR vaccine. A mild rash develops in about 5 percent of children and may be accompanied by slight lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/20,33\">",
"     20,33",
"    </a>",
"    ]. Joint manifestations are uncommon among young children. Approximately 0.5 percent develops arthralgias, usually of the small peripheral joints.",
"   </p>",
"   <p>",
"    Among postpubertal females, arthralgias develop in approximately 25 percent of cases and transient arthritis in about 10 percent, usually 7 to 21 days after immunization. The frequency of such joint manifestations after immunization is less than after natural infection. Transient paresthesias and pain in the extremities have been reported rarely. An acute peripheral neuritis (catcher's crouch syndrome) has been associated with previous live-attenuated rubella vaccines, but is rare with the RA",
"    <span class=\"nowrap\">",
"     27/3",
"    </span>",
"    vaccine.",
"   </p>",
"   <p>",
"    No casual relationship exists between MMR vaccination and autism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/37-39\">",
"     37-39",
"    </a>",
"    ], chronic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/40\">",
"     40",
"    </a>",
"    ], rheumatologic and other chronic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/41\">",
"     41",
"    </a>",
"    ], aseptic meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/42\">",
"     42",
"    </a>",
"    ], cerebellar ataxia, or Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rubella vaccination is contraindicated during pregnancy. The vaccine virus can cross the placenta, and fetal infection with vaccine strains has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/44\">",
"     44",
"    </a>",
"    ]. Many countries, including the United States, recommend that women do not become pregnant until at least one month following vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/20,45\">",
"     20,45",
"    </a>",
"    ]. Should inadvertent vaccine administration occur during pregnancy, therapeutic abortion is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/20\">",
"     20",
"    </a>",
"    ]. A small percent of fetuses may be infected but congenital defects have not been shown to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/20,33\">",
"     20,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Allergic reactions are rare and usually minor, consisting mostly of wheal and flare reactions or urticaria at the site of the injection. Such reactions have been attributed to the trace amount of gelatin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    , and other components of the vaccine. The vaccine is grown in chicken embryo cell cultures, but contains insignificant amounts of ovalbumin cross-reacting proteins. Hence, anaphylactic reactions are rare, and skin testing of those with a history of egg allergy is not required.",
"   </p>",
"   <p>",
"    Rubella vaccine may be administered to susceptible family members of immunocompromised patients and to health care workers caring for immunocompromised patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/20,33\">",
"     20,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Control measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control measures for postnatal rubella include droplet precautions and exclusion from school or child care for seven days after the onset of the rash [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26855/abstract/20,46\">",
"     20,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/10/14499?source=see_link\">",
"       \"Patient information: Rubella (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rubella (German measles) is a viral infection typically characterized by rash, fever, and lymphadenopathy. The rash is usually an erythematous, discrete maculopapular exanthem that begins on the face and spreads caudally. It usually disappears within three days but may persist for eight days. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rubella is acquired through the inhalation of large particle aerosols of infectious secretions with initial infection of nasopharyngeal cells and subsequent viremia and spread to other body sites. The incubation period is usually 14 to 18 days with a range of 12 to 23 days. Virus may be shed for up to one to two weeks prior to the appearance of the rash. Patients may be contagious one to two weeks before the infection becomes clinically apparent. Subclinical or asymptomatic infection is common. Viral shedding decreases concurrent with the appearance of the rash and the development of neutralizing antibodies. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to the introduction of the rubella vaccine, outbreaks of rubella occurred at variable intervals of three to six or more years, with the highest incidence among school children. Precipitous declines in rubella cases occurred with the routine immunization of young children, and rubella has not been endemic in the United States since 2004. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology and vaccine development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rubella infection during pregnancy can lead to fetal death, premature delivery, and a myriad of congenital abnormalities. The most common manifestations of congenital rubella syndrome are hearing loss, developmental delay, growth retardation, and cardiac and ophthalmic defects. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Congenital rubella syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory diagnosis of rubella is warranted when congenital rubella syndrome is suspected or when the diagnosis is sought for a condition compatible with the known complications of postnatal rubella, such as arthritis. Serologic assays, primarily enzyme immunoassays (EIA), are used most frequently. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management consists of supportive care. No specific therapy exists for rubella infection. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of rubella vaccination is to prevent congenital rubella infection. In accordance with the United States Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) we recommend that all children receive appropriate rubella vaccination (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In the United States, the recommendations are for routine immunization with MMR or MMR combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      (MMRV) administered at 12 to 15 months of age, with a second dose of MMR at four to six years when entering school. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaccination should also be administered to susceptible health care workers and non-immune women of childbearing age who are not pregnant. However, should inadvertent vaccine administration occur during pregnancy, therapeutic abortion is not warranted (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Prevention'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2143218\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Caroline Breese Hall, MD who passed away in December 2012. We wish to acknowledge Dr. Hall&rsquo;s many contributions to UpToDate, in particular her work as an author of this topic.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/1\">",
"      Griffith JPC. Rubella (R&ouml;theln: German Measles): With a report of one hundred and fifty cases. Med Rec 1887; 32:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/2\">",
"      Veale H. History of an epidemic of R&ouml;theln, with observation on its pathology. Edin Med J 1866; 12:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/3\">",
"      Hess AF. German measles (rubella): an experimental study. Arch Intern Med Chicago 1914; 13:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/4\">",
"      Hiro VY, Tasaka S. Die R&ouml;teln sind eine Viruskrankheit. Monatsschr. Kinderheilk 1938; 76:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/5\">",
"      Gregg NM. Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Aust 1941; 3:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/6\">",
"      Aksit S, Egemen A, Ozacar T, et al. Rubella seroprevalence in an unvaccinated population in Izmir: recommendations for rubella vaccination in Turkey. Pediatr Infect Dis J 1999; 18:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward elimination of measles and prevention of congenital rubella infection--European region, 1990-2004. MMWR Morb Mortal Wkly Rep 2005; 54:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/8\">",
"      Cutts FT, Robertson SE, Diaz-Ortega JL, Samuel R. Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 1: Burden of disease from CRS. Bull World Health Organ 1997; 75:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/9\">",
"      Onyenekwe CC, Kehinde-Agbeyangi TA, Ofor US, Arinola OG. Prevalence of rubella-IgG antibody in women of childbearing age in Lagos, Nigeria. West Afr J Med 2000; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/10\">",
"      Robertson SE, Featherstone DA, Gacic-Dobo M, Hersh BS. Rubella and congenital rubella syndrome: global update. Rev Panam Salud Publica 2003; 14:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/11\">",
"      Wynter SH, O'Gilvie CR, Khan C, et al. Rubella susceptibility in Jamaican women, 1996. West Indian Med J 1999; 48:123.",
"     </a>",
"    </li>",
"    <li>",
"     Hobman T, Chantler J. Rubella virus. In: Fields Virology, 5th Ed, Lippincott Williams &amp; Wilkins, Philadelphia 2007. p.1069.",
"    </li>",
"    <li>",
"     Plotkin SA, Reef SE. Rubella vaccine. In: Vaccines, 5th Ed, Plotkin S, Orsenstein W, Offit P (Eds), Saunders Elsevier, Philadelphia 2008. p.735.",
"    </li>",
"    <li>",
"     Best JM, Icenogle JP, Brown DWG. Rubella. In: Principles and Practices of Clinical Virology, 6th Ed, Zuckerman AJ, Banatvala JE, Schoub BD, et al (Eds), John Wiley &amp; Sons, Ltd, West Sussex, UK 2009. p.561.",
"    </li>",
"    <li>",
"     Plotkin SA. History of rubella and the recent history of cell culture. In: Vaccinia, Vaccination, Vaccinology: Jenner, Pasteur and their Successors, Plotkin S, Fantini B (Eds), Elsevier, Paris 1996. p.271.",
"    </li>",
"    <li>",
"     CDC. Rubella. In: Epidemiology and Prevention of Vaccine-Preventable Diseases, 12th Ed, Atkinson W, Wolfe C, Hamborsky (Eds), Public Health Foundation, Washington, DC 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/17\">",
"      Castillo-Solorzano C C, Matus CR, Flannery B, et al. The Americas: paving the road toward global measles eradication. J Infect Dis 2011; 204 Suppl 1:S270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/18\">",
"      Reef SE, Cochi SL. The evidence for the elimination of rubella and congenital rubella syndrome in the United States: a public health achievement. Clin Infect Dis 2006; 43 Suppl 3:S123.",
"     </a>",
"    </li>",
"    <li>",
"     Cherry JD. Rubella virus. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 6th Ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders Elsevier, Philadelphia 2009. p.2271.",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Rubella. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.629.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/21\">",
"      Best JM. Rubella. Semin Fetal Neonatal Med 2007; 12:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/22\">",
"      Best JM, O'Shea S, Tipples G, et al. Interpretation of rubella serology in pregnancy--pitfalls and problems. BMJ 2002; 325:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/23\">",
"      Morgan-Capner P, Miller E, Vurdien JE, Ramsay ME. Outcome of pregnancy after maternal reinfection with rubella. CDR (Lond Engl Rev) 1991; 1:R57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/24\">",
"      Duszak RS. Congenital rubella syndrome--major review. Optometry 2009; 80:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/25\">",
"      O'Neill JF. The ocular manifestations of congenital infection: a study of the early effect and long-term outcome of maternally transmitted rubella and toxoplasmosis. Trans Am Ophthalmol Soc 1998; 96:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/26\">",
"      Reef SE, Plotkin S, Cordero JF, et al. Preparing for elimination of congenital Rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States. Clin Infect Dis 2000; 31:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/27\">",
"      Dimech W, Panagiotopoulos L, Marler J, et al. Evaluation of three immunoassays used for detection of anti-rubella virus immunoglobulin M antibodies. Clin Diagn Lab Immunol 2005; 12:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/28\">",
"      Thomas HI, Morgan-Capner P, Cradock-Watson JE, et al. Slow maturation of IgG1 avidity and persistence of specific IgM in congenital rubella: implications for diagnosis and immunopathology. J Med Virol 1993; 41:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/29\">",
"      B&ouml;ttiger B, Jensen IP. Maturation of rubella IgG avidity over time after acute rubella infection. Clin Diagn Virol 1997; 8:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/30\">",
"      Mac&eacute; M, Cointe D, Six C, et al. Diagnostic value of reverse transcription-PCR of amniotic fluid for prenatal diagnosis of congenital rubella infection in pregnant women with confirmed primary rubella infection. J Clin Microbiol 2004; 42:4818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/31\">",
"      Galazka A. Rubella in Europe. Epidemiol Infect 1991; 107:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/32\">",
"      Marin M, Broder KR, Temte JL, et al. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/33\">",
"      Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/34\">",
"      ACIP Childhood/Adolescent Immunization Work Group, Akinsanya-Beysolow I, Jenkins R, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/35\">",
"      Braun C, Kampa D, Fressle R, et al. Congenital rubella syndrome despite repeated vaccination of the mother: a coincidence of vaccine failure with failure to vaccinate. Acta Paediatr 1994; 83:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/36\">",
"      Parkman PD. Making vaccination policy: the experience with rubella. Clin Infect Dis 1999; 28 Suppl 2:S140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/37\">",
"      Elliman D, Bedford H. MMR: where are we now? Arch Dis Child 2007; 92:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/38\">",
"      Gerber JS, Offit PA. Vaccines and autism: a tale of shifting hypotheses. Clin Infect Dis 2009; 48:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/39\">",
"      Mrozek-Budzyn D, Kietyka A, Majewska R. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatr Infect Dis J 2010; 29:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/40\">",
"      Ray P, Black S, Shinefield H, et al. Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team. JAMA 1997; 278:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/41\">",
"      Larson EB. Adult Still's disease. Evolution of a clinical syndrome and diagnosis, treatment, and follow-up of 17 patients. Medicine (Baltimore) 1984; 63:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/42\">",
"      Groves FD, Gridley G, Wacholder S, et al. Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA. Br J Cancer 1999; 81:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/43\">",
"      MMR vaccine is not linked to Crohn's disease or autism. Commun Dis Rep CDR Wkly 1998; 8:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/44\">",
"      Yamauchi T, Wilson C, Geme JW Jr. Transmission of live, attenuated mumps virus to the human placenta. N Engl J Med 1974; 290:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26855/abstract/45\">",
"      Centers for Disease Control and Prevention (CDC). Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. MMWR Morb Mortal Wkly Rep 2001; 50:1117.",
"     </a>",
"    </li>",
"    <li>",
"     Hayden G. Rubella (German measles). In: Infection Control in the Child Care Center and Preschool, 8th Ed, Grossman L.  (Ed), Demos Medical Publishing, New York 2012. p.264.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8301 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_14_26855=[""].join("\n");
var outline_f26_14_26855=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY AND VACCINE DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Global occurrence of rubella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Congenital rubella syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Control measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2143218\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8301\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8301|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/22/17775\" title=\"figure 1\">",
"      Rubella CRS epidemiology US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8301|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/17/10513\" title=\"picture 1\">",
"      Rubella rash",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=related_link\">",
"      Congenital rubella syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36855?source=related_link\">",
"      Congenital rubella syndrome: Management, outcome, and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/10/14499?source=related_link\">",
"      Patient information: Rubella (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6087?source=related_link\">",
"      Rubella in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_14_26856="Pustular psoriasis - plaques";
var content_f26_14_26856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56926%7EDERM%2F67402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56926%7EDERM%2F67402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pustular psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous small pustules are present on erythematous plaques.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Callen, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pustules in pustular psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_14_26856=[""].join("\n");
var outline_f26_14_26856=null;
var title_f26_14_26857="Autism and chronic disease: Little evidence for vaccines as a contributing factor";
var content_f26_14_26857=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Autism and chronic disease: Little evidence for vaccines as a contributing factor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/14/26857/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/14/26857/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/14/26857/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/14/26857/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/14/26857/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/14/26857/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/14/26857/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the 1980s, there appears to have been an increase in the number of cases of autism diagnosed in the United States and other parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. Rates of autism spectrum disorders in studies from the late 1990s are consistently greater than 10 per 10,000 compared with four to five per 10,000 in previous decades [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/9\">",
"     9",
"    </a>",
"    ]. Active surveillance in the United States suggests a prevalence of approximately 1 in 90 eight-year-old children in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=see_link&amp;anchor=H9#H9\">",
"     \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\", section on 'Prevalence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This real or perceived increase in autism cases has occurred at a time when there has been a significant increase in the number of recommended childhood vaccines. In the search for a causal relationship, parents of autistic children and some professionals have identified a temporal association between immunizations and the onset of more evident symptoms of autism in the second year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/7\">",
"     7",
"    </a>",
"    ]. It has been suggested that certain vaccines (eg, measles, mumps, and rubella [MMR]) and vaccine constituents (eg, thimerosal) play a role in the development of autism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]. Vaccines and vaccine constituents have also been linked with the development of other chronic diseases, such as multiple sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/16-18\">",
"     16-18",
"    </a>",
"    ] and diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Research to prove or disprove a possible relationship between the various components of recommended childhood vaccines and chronic diseases such as autism is ongoing. However, to date, no scientific linkage has been established. The evidence for and against an association between vaccines and autism and chronic disease will be presented here. The evidence for and against an association between thimerosal and autism and chronic disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21066?source=see_link\">",
"     \"Autism and chronic disease: Little evidence for thimerosal as a contributing factor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of autism spectrum disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=see_link\">",
"     \"Clinical features of autism spectrum disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=see_link\">",
"     \"Diagnosis of autism spectrum disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPARENT INCREASE IN AUTISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the 1980s, there appears to have been an increase in the number of cases of autism diagnosed in the United States and other parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. Much attention was generated when the California Department of Developmental Services reported a 210 percent increase in the number of persons with autism between 1987 and 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/1\">",
"     1",
"    </a>",
"    ]. Adequate explanation for the increase was not clear, though there was speculation that changes in diagnostic criteria and an increased awareness of the conditions among health-care providers and developmental specialists may have been contributing factors. Subsequent reports analyzing data from cohorts of children with autism from regional developmental centers in California reached opposite conclusions about whether the apparent rise in cases of autism were attributable to changes in diagnostic criteria, misclassification, or in-migration to a generous service system [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=see_link&amp;anchor=H8#H8\">",
"     \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Comparing studies with different case definitions, methods of case finding, and sample populations is problematic unless there is rigorous control for these variables [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/9\">",
"     9",
"    </a>",
"    ]. Systematic reviews of the epidemiologic studies of autism have found evidence that changes in case definition and increased awareness account for much of the increased prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/9,23,24\">",
"     9,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     POSSIBLE ASSOCIATION BETWEEN AUTISM AND MMR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The real or perceived increase in autism cases occurred at a time when the number of recommended childhood vaccines also increased (to include",
"    <em>",
"     Haemophilus influenza",
"    </em>",
"    type b [Hib], hepatitis B, varicella, and pneumococcal vaccines, as well as a second dose of the measles, mumps, and rubella [MMR] vaccine). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"     \"Standard immunizations for children and adolescents\"",
"    </a>",
"    .) In the search for a causal relationship, parents of autistic children and some professionals identified a temporal association of immunizations with the onset of more evident symptoms of autism in the second year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the temporal association, concern about a potential association between autism and MMR vaccine comes primarily from two reports describing a link between MMR vaccine, gastrointestinal complaints, and autism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/10,25\">",
"     10,25",
"    </a>",
"    ]. The first report described chronic enterocolitis in children with neuropsychiatric dysfunction, including autism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/10\">",
"     10",
"    </a>",
"    ]. This paper was retracted from the public record in 2010, and exposed as fraudulent in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The second report described increased presence of persistent measles virus in the intestinal tissue of children with developmental disorders compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Enterocolitis and regression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alleged association between MMR, enterocolitis, and autism was first reported in a 1998 study of 12 children that suggested a link between recent injection of MMR vaccine and the onset of symptoms of autism and enterocolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/10\">",
"     10",
"    </a>",
"    ]. However, by comparing the case descriptions in the paper with medical records, an investigative reporter found that the study was fraudulent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/27\">",
"     27",
"    </a>",
"    ]. Three of the children did not have autism; five had developmental concerns before MMR vaccination; behavioral symptoms developed in some children months (rather than days) after MMR vaccination; and colonoscopy results were altered from unremarkable findings to &ldquo;nonspecific colitis&rdquo; after &ldquo;research review&rdquo;. In addition, patients were recruited through an anti-MMR organization and the study was commissioned and funded for planned litigation. Ten of the 13 authors of the study published a statement retracting its interpretation in 2004, and the Lancet fully retracted the paper in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/26,28\">",
"     26,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Persistent intestinal measles virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second study compared the presence of persistent measles virus in the intestinal tissue of 91 children with developmental disorders, including autism, and 70 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/25\">",
"     25",
"    </a>",
"    ]. Persistent measles virus particles were more prevalent among the children with developmental disorders (82 versus 7 percent). The authors concluded that the data confirm an association between the presence of measles virus and gut pathology in children with developmental disorder.",
"   </p>",
"   <p>",
"    This study and its conclusions have been criticized and contradicted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. The criticisms include a number of methodologic flaws [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is plausible that in the natural course of response to the live-attenuated measles vaccine, including the virus being taken up by antigen-presenting cell, that measles virus genome could be detected in the intestine and other body tissues, particularly with a very sensitive assay (as was used)",
"     </li>",
"     <li>",
"      Information about whether and when cases and controls had received the MMR vaccine was not reported; such information is critical in determining whether the MMR vaccine causes autism [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      It was not determined whether the virus genome that was detected was from vaccine virus or natural measles virus (which is still circulating in England)",
"     </li>",
"     <li>",
"      Measures to prevent false-positive results from natural measles virus contamination in the laboratory were not described, nor was blinding of the laboratory personnel",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LACK OF EVIDENCE FOR ASSOCIATION BETWEEN AUTISM AND MMR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Biologic mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the criteria for establishing causality is that there is a coherent explanation that accounts for the findings (ie, a plausible biologic mechanism) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/34\">",
"     34",
"    </a>",
"    ]. Decreased viral immunity, caused by the measles, mumps, and rubella (MMR) vaccine, has been proposed as a mechanism for the association between MMR and autism spectrum disorders (ASD) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/11\">",
"     11",
"    </a>",
"    ]. However, there is insufficient evidence to support this view [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/29,35\">",
"     29,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autoimmunity, persistent gastrointestinal (GI) measles virus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/25,36\">",
"     25,36",
"    </a>",
"    ], and opioid excess [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/10\">",
"     10",
"    </a>",
"    ] have been proposed to explain the association between MMR, bowel disease, and",
"    <span class=\"nowrap\">",
"     autism/ASD",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/29\">",
"     29",
"    </a>",
"    ]. However, evidence to support these mechanisms is lacking:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Characteristic markers for immune injury or inflammation are not present in patients with autism [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/29,37\">",
"       29,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although there is support for persistent central nervous system (CNS) measles vaccine virus causing neuropsychiatric dysfunction in immunocompromised individuals as a possible mechanism [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/38,39\">",
"       38,39",
"      </a>",
"      ], the presence of vaccine-strain measles virus mRNA has not been demonstrated in the CNS or other tissues of healthy individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Using polymerase chain reaction (PCR) technology, several investigators have reported the presence of measles virus in intestinal or blood samples of children with autism spectrum disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/25,36,40\">",
"       25,36,40",
"      </a>",
"      ]. However, subsequent studies using highly sensitive and specific assays and enhanced laboratory techniques failed to detect measles virus nucleic acids in the white blood cells of children with autism who had received MMR vaccine, suggesting that the findings in the earlier studies may have been false positives [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/41-43\">",
"       41-43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case-control study evaluated the presence of measles virus RNA (with PCR)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inflammation in bowel tissue and the temporal relation between MMR administration and onset of ASD",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      GI disturbances in 23 children with GI disturbances and ASD and nine children with isolated GI disturbances [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/44\">",
"       44",
"      </a>",
"      ]. The presence of measles virus RNA was assayed in three laboratories, including the one from which the findings suggesting a link between MMR and autism were reported [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/10\">",
"       10",
"      </a>",
"      ]. The laboratories were blinded to the diagnosis. The results were consistent across laboratories: measles virus RNA was detected in one patient in each group. The timing of MMR, onset of GI disturbances, and onset of autism was not consistent with MMR vaccine as a trigger of GI disturbances or ASD.",
"     </li>",
"     <li>",
"      Another case-control study found no differences in the excretion of opioid peptides in the urine of children with ASD or controls [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/45\">",
"       45",
"      </a>",
"      ]. Cerebrospinal beta-endorphins in patients with autism are not consistently elevated [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/46-48\">",
"       46-48",
"      </a>",
"      ], nor do social and stereotypic behaviors in children with ASD improve with administration of opioid antagonists [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/49-51\">",
"       49-51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Persistent measles infection or abnormally persistent immune response to MMR is another mechanism that has been proposed to explain an association between MMR and autism. Support for this hypothesis was lacking in a case-control study in which measles virus and measles antibody were measured in 98 children (aged 10 to 12 years) with ASD, 52 children with special needs without ASD, and 90 typically developing children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/52\">",
"     52",
"    </a>",
"    ]. Measles virus nucleic acid was detected in peripheral blood mononuclear cells of one child with ASD and two typically developing children. Antibody response did not differ between cases and controls and there was no correlation between antibody levels and autism symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Epidemiologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;To determine whether the MMR vaccine actually causes autism, it is necessary to compare the relative risk of developing autism among children who did and did not receive the MMR vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. Such epidemiologic methods have been used to detect associations between the swine flu vaccine and Guillain-Barr&eacute; syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/53\">",
"     53",
"    </a>",
"    ], the Rotashield vaccine and intussusception [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/54\">",
"     54",
"    </a>",
"    ], and the MMR vaccine and immune thrombocytopenia (ITP) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/55\">",
"     55",
"    </a>",
"    ]. In contrast, several large epidemiologic studies have failed to detect an association between MMR vaccine and autism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/3,56-63\">",
"     3,56-63",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of autism among vaccinated and unvaccinated children was compared in a retrospective cohort study of all children born in Denmark between January 1991 and December 1998 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/3\">",
"       3",
"      </a>",
"      ]. Among the 537,303 children in the cohort, 838 (&lt;1 percent) had autism or ASD, and 82 percent had received the MMR vaccine. After adjustment for potential confounders, the relative risk of autism among the vaccinated children was 0.92 (95% CI 0.68-1.24), and the relative risk of ASD among the vaccinated children was 0.83 (95% CI 0.65-1.07). In addition to the lack of association between MMR vaccine and",
"      <span class=\"nowrap\">",
"       autism/ASD,",
"      </span>",
"      no association was found between the age at the time of vaccination, the time since vaccination, or the date of vaccination and the development of autism or ASD.",
"     </li>",
"     <li>",
"      A population-based study from the United Kingdom investigated the incidence of autism before and after the introduction of MMR vaccine in 1988 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/56\">",
"       56",
"      </a>",
"      ]. Although there was a steady increase in the number of cases of autism by year of birth, there was no sudden change in the trend after the introduction of the MMR vaccine. Moreover, there was no difference in the age of diagnosis of autism between the cases vaccinated before or after 18 months of age and those never vaccinated. The analysis failed to support a causal relationship between receipt of the MMR vaccine and subsequent development of autism [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/56\">",
"       56",
"      </a>",
"      ]. A similar retrospective analysis in the United States came to the same conclusion [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a population-based study from Montreal, rates of ASD increased as MMR vaccination coverage decreased [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/62\">",
"       62",
"      </a>",
"      ]. In addition, the rate of increased prevalence of ASD was similar before and after the introduction of a second dose of MMR vaccine to the routine childhood immunization schedule [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A population-based case-control study in the United States, which hypothesized that earlier age at vaccination might be associated with an increased risk for autism, failed to detect such an association [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A matched case-control study using the UK General Practice Research Database found no association between receipt of the MMR vaccine and autism or pervasive developmental disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      After the introduction of the MMR vaccine in Finland in 1982, a countrywide surveillance program was established to determine the incidence and nature of serious adverse events [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/58-60\">",
"       58-60",
"      </a>",
"      ]. Among children who received the vaccine between 1982 and 1986, there was no clustering of hospitalizations for autism related to MMR administration, nor was there an increase in cases of encephalitis or aseptic meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/58\">",
"       58",
"      </a>",
"      ]. Among 31 children who reported gastrointestinal symptoms after the vaccine, no cases of ASD were reported or identified; mean follow-up was 9.25 years (range of 1.3 to 15.1 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a population study, bowel problems and developmental regression among 473 children with autism or ASD were examined between 1979 and 1998, and related to MMR vaccine (which was introduced in 1988) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/56\">",
"       56",
"      </a>",
"      ]. The proportion of children with bowel symptoms or developmental regression did not change after the introduction of the MMR vaccine. In addition, the rates of bowel problems and regression among children who received the MMR vaccine before their parents were concerned about their development were similar to the rates among children who received the vaccine after their parents were concerned about their development and those who did not receive the vaccine. These findings do not support an association between MMR vaccine and autism.",
"     </li>",
"     <li>",
"      In a total population study in Yokohama, Japan, the incidence of ASD among 31,426 children born between 1988 and 1996 increased from 48 to 117 cases per 10,000 children [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/64\">",
"       64",
"      </a>",
"      ]. The increased incidence in ASD occurred despite decline in MMR vaccination rate from 70 to 0 percent in 1993, after which MMR vaccination was replaced with monovalent measles and rubella vaccines (mumps vaccination was terminated because of concerns regarding aseptic meningitis as a possible side-effect).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systematic reviews of the epidemiologic evidence also have failed to find support for an association between the MMR vaccine and",
"    <span class=\"nowrap\">",
"     autism/ASD",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. As an example, the Institute of Medicine (IOM) committee to review adverse effects of vaccines reviewed evidence from 22 studies and concluded that existing evidence favors rejection of a causal relationship between MMR and autism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research to prove or disprove a possible relationship between MMR and autism is ongoing. However, to date, no scientific linkage has been established.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proposed biologic mechanisms that have been generated are only theoretical [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Multiple large, well-designed epidemiologic studies [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/2-5,31,56,58,67\">",
"       2-5,31,56,58,67",
"      </a>",
"      ] and systematic reviews [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/35,65,66\">",
"       35,65,66",
"      </a>",
"      ] have found insufficient evidence to support an association between the MMR vaccine and autism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The inability to absolutely exclude an association between the MMR vaccine and autism stems from the limitations of the scientific method [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/32\">",
"     32",
"    </a>",
"    ], in which the null hypothesis (ie, that MMR vaccine does not cause autism) can be rejected or not rejected, but cannot be accepted. Thus, in strict adherence to the scientific method, one cannot accept the null hypothesis and conclude that the MMR vaccine does not cause autism, because this would imply that the MMR vaccine never causes autism, something that cannot be proven. However, in its latest review, the Immunization Safety Review Committee of the IOM concludes that the evidence favors rejection of a causal relationship between MMR vaccine and autism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OTHER CHRONIC DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to autism, other chronic diseases, including multiple sclerosis and diabetes, have been attributed to the proximate receipt of vaccines in certain individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Multiple sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been concern that onset or relapse of multiple sclerosis was precipitated by hepatitis B or other vaccines. The relationship between multiple sclerosis and vaccines is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\", section on 'Role of immune system stimuli'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Type 1 diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been reports of clustering of cases of type 1 diabetes mellitus (DM) linked temporally to",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b vaccine, pertussis vaccine, measles, mumps, and rubella (MMR), and BCG vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/19\">",
"     19",
"    </a>",
"    ], and concerns that the timing of the first dose of vaccine may affect the risk of development of type 1 diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The studies linking type 1 diabetes mellitus and various vaccines were performed by comparing the rates of diabetes and vaccination schedules among various countries, and searching databases on the incidence of type 1 diabetes in various regions and then determining whether changes in immunization occurred during the time the incidence of DM was recorded [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such ecologic studies may provide the basis for a hypothesis that a vaccine is associated with a particular disease, but do not provide evidence for the association. Many factors may affect the rates of diabetes between various countries (eg, genetic predisposition, environmental exposures, breastfeeding, etc). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23210?source=see_link\">",
"     \"Pathogenesis of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To provide evidence of an association between a particular vaccine and diabetes mellitus, it is necessary to compare the relative risk of developing type 1 diabetes among children who did and did not receive the particular vaccine. Two large, population-based, case-control studies found no association between any of the routinely recommended childhood vaccines and an increased risk of type 1 diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/68,69\">",
"     68,69",
"    </a>",
"    ], nor has an association between type 1 diabetes and childhood vaccination been detected in large population-based cohort studies in Sweden, Finland, and Denmark [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/70-72\">",
"     70-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One potential mechanism for an association between vaccine administration and development of type 1 diabetes is that the vaccines stimulate beta cell autoimmunity. However, in a prospective cohort of children who had a first-degree relative with type 1 diabetes mellitus, development of beta-cell autoimmunity was not associated with HepB, Hib, polio, or DTP vaccines administered before nine months of age, time of receipt of first HepB vaccine, or median age at first HepB, Hib, polio, or DTP vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/73\">",
"     73",
"    </a>",
"    ]. In another study, vaccination against tuberculosis, smallpox, tetanus, pertussis, rubella, and mumps had no effect on the risk of developing type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/74\">",
"     74",
"    </a>",
"    ]. On the other hand, there is some evidence that measles vaccine may decrease the risk of diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23210?source=see_link\">",
"     \"Pathogenesis of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROVEN BENEFITS OF VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, there is a lack of evidence for an association between vaccines and chronic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/76\">",
"     76",
"    </a>",
"    ]. On the other hand, the benefits of vaccines are clear. As illustrated below, several infectious diseases that were once associated with significant morbidity and mortality have been almost completely eliminated through the development, distribution, and almost universal administration of protective vaccines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wild-strain poliomyelitis has been eliminated from the Western hemisphere. No case has been reported in the United States since 1979. The last known case in the Western hemisphere was reported in Peru in 1992. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=see_link\">",
"       \"Poliovirus vaccination\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The number of reported measles cases in the United States has fallen substantially since the early 1990s, when the uniform recommendation was made that all children, adolescents, and young adults without history of natural measles disease receive two doses of measles vaccine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link\">",
"       \"Clinical presentation and diagnosis of measles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Between 1987 (when the",
"      <em>",
"       H. influenzae",
"      </em>",
"      type b [Hib] conjugate vaccine was introduced in the United States) and 2000, the number of invasive Hib cases in children younger than five years of age declined by &gt;99 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/77,78\">",
"       77,78",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41608?source=see_link\">",
"       \"Microbiology, epidemiology and treatment of Haemophilus influenzae\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the declining incidence of these once-common infectious diseases, parents of young children may no longer appreciate the potential severity or dire consequences of the illnesses. Parents who lack such appreciation may be willing to forego immunizations for their children, particularly if unproven risks (eg,",
"    <span class=\"nowrap\">",
"     autism/autism",
"    </span>",
"    spectrum disorders) are highly publicized [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/79\">",
"     79",
"    </a>",
"    ]. When this occurs, immunization rates decline, and outbreaks of infectious diseases, such as measles and pertussis, may occur with significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/32,80-84\">",
"     32,80-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, between 35 and 100 of every 100,000 patients with measles disease develop acute encephalitis, which has a mortality rate of 10 percent and causes neurologic damage in 25 percent of survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/58,82,85,86\">",
"     58,82,85,86",
"    </a>",
"    ]. In addition to acute encephalitis, meningitis, subacute sclerosing panencephalitis, and acute disseminated encephalomyelitis have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/58,85,87\">",
"     58,85,87",
"    </a>",
"    ]. Even in uncomplicated cases of measles, as many as 50 percent of patients may have EEG changes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26857/abstract/58,88\">",
"     58,88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link\">",
"     \"Clinical presentation and diagnosis of measles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=see_link\">",
"       \"Patient information: Why does my child need vaccines? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/46/41699?source=see_link\">",
"       \"Patient information: Autism spectrum disorders (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15594403\">",
"    <span class=\"h1\">",
"     OUTSIDE SOURCES OF PATIENT EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following Web sites from the US Centers for Disease Control and Prevention (CDC), the United Kingdom's National Health Service, the Immunization Action Coalition, and the Australian National Centre for Immunisation Research and Surveillance (NCIRS) provide additional information about vaccines and autism and diabetes. They include sections on frequently asked questions that may be helpful when discussing these issues with parents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.cdc.gov/vaccinesafety/concerns/autism/index.html\">",
"       www.cdc.gov/vaccinesafety/Concerns/Autism/Index.html",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.nhs.uk/conditions/mmr/pages/introduction.aspx\">",
"       www.nhs.uk/conditions/mmr/Pages/Introduction.aspx",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.immunize.org/catg.d/p4026.pdf\">",
"       www.immunize.org/catg.d/p4026.pdf",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.immunize.org/catg.d/p4028.pdf\">",
"       www.immunize.org/catg.d/p4028.pdf",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.ncirs.edu.au/immunisation/fact-sheets/diabetes-and-vaccines-fact-sheet.pdf\">",
"       www.ncirs.edu.au/immunisation/fact-sheets/diabetes-and-vaccines-fact-sheet.pdf",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of autism and autism spectrum disorders (ASD) appears to have increased over the last several decades. Much of this trend is accounted for by changes in case definition and increased awareness of autism. Whether or not the actual incidence of autism has increased is unclear. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Apparent increase in autism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple large, well-designed epidemiologic studies and systematic reviews have found insufficient evidence to support an association between the measles, mumps, and rubella (MMR) vaccine and autism. In its latest review, the Immunization Safety Review Committee of the Institute of Medicine (IOM) concludes that the evidence favors rejection of a causal relationship between MMR vaccine and autism. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Lack of evidence for association between autism and MMR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Similarly, well-designed epidemiologic studies have failed to find an association between vaccines and multiple sclerosis or type 1 diabetes mellitus. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Other chronic diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The administration of childhood vaccines has led to a decline in the incidence of childhood diseases that can have severe sequelae. Withholding vaccines from a child because of a hypothetical risk places the child at risk for actual infection that may have actual sequelae. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Proven benefits of vaccines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Though neither specific childhood vaccines nor vaccine components, such as thimerosal, have been proven by scientific study to have a causal relationship with the development of autism, there is evidence that other factors, including genetics, are important in the development of autism. These factors are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=see_link&amp;anchor=H12#H12\">",
"       \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Department of Developmental Services. Changes in the population of persons with autism and pervasive developmental disorders in California's developmental services system: 1987 through 1998. A Report to the Legislature. California Health and Human Services, March 1, 1999. file://www.dds.ca.gov/Autism/docs/autism_report_1999.pdf (Accessed on October 05, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/2\">",
"      Dales L, Hammer SJ, Smith NJ. Time trends in autism and in MMR immunization coverage in California. JAMA 2001; 285:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/3\">",
"      Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002; 347:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/4\">",
"      Madsen KM, Lauritsen MB, Pedersen CB, et al. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics 2003; 112:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/5\">",
"      Kaye JA, del Mar Melero-Montes M, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ 2001; 322:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/6\">",
"      Yeargin-Allsopp M, Rice C, Karapurkar T, et al. Prevalence of autism in a US metropolitan area. JAMA 2003; 289:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/7\">",
"      McCormick MC. The autism \"epidemic\": impressions from the perspective of immunization safety review. Ambul Pediatr 2003; 3:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/8\">",
"      Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators, Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/9\">",
"      Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res 2009; 65:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/10\">",
"      Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/11\">",
"      Wakefield AJ, Montgomery SM. Autism, viral infection and measles-mumps-rubella vaccination. Isr Med Assoc J 1999; 1:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/12\">",
"      Bernard S, Enayati A, Redwood L, et al. Autism: a novel form of mercury poisoning. Med Hypotheses 2001; 56:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/13\">",
"      Bernard S, Enayati A, Roger H, et al. The role of mercury in the pathogenesis of autism. Mol Psychiatry 2002; 7 Suppl 2:S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/14\">",
"      Geier MR, Geier DA. Thimerosal in childhood vaccines, neurodevelopment disorders and heart disease in the United States. J Am Physicians Surg 2003; 8:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/15\">",
"      Geier MR, Geier DA. Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication. Exp Biol Med (Maywood) 2003; 228:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/16\">",
"      I&ntilde;iguez C, Mauri JA, Larrod&eacute; P, et al. [Acute transverse myelitis secondary to hepatitis B vaccination]. Rev Neurol 2000; 31:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/17\">",
"      Herroelen L, de Keyser J, Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet 1991; 338:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/18\">",
"      Marshall E. A shadow falls on hepatitis B vaccination effort. Science 1998; 281:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/19\">",
"      Classen JB, Classen DC. Clustering of cases of type 1 diabetes mellitus occurring 2-4 years after vaccination is consistent with clustering after infections and progression to type 1 diabetes mellitus in autoantibody positive individuals. J Pediatr Endocrinol Metab 2003; 16:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/20\">",
"      Classen DC, Classen JB. The timing of pediatric immunisation and the risk of insulin-dependent diabetes mellitus. Infectious Dis Clin Pract 1997; 6:449.",
"     </a>",
"    </li>",
"    <li>",
"     Byrd, RS, Segman, M, Bono, M. Report to the Legislature on the principal findings from the epidemiology of autism in California: a comprehensive pilot study. University of California, Davis, M.I.N.D. Institute, October 17, 2002. file://www.dds.ca.gov/Autism/docs/study_final.pdf (Accessed on October 05, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/22\">",
"      Croen LA, Grether JK, Hoogstrate J, Selvin S. The changing prevalence of autism in California. J Autism Dev Disord 2002; 32:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/23\">",
"      Wing L, Potter D. The epidemiology of autistic spectrum disorders: is the prevalence rising? Ment Retard Dev Disabil Res Rev 2002; 8:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/24\">",
"      Shattuck PT. The contribution of diagnostic substitution to the growing administrative prevalence of autism in US special education. Pediatrics 2006; 117:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/25\">",
"      Uhlmann V, Martin CM, Sheils O, et al. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. Mol Pathol 2002; 55:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/26\">",
"      Retraction--Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 2010; 375:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/27\">",
"      Deer B. How the case against the MMR vaccine was fixed. BMJ 2011; 342:c5347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/28\">",
"      Murch SH, Anthony A, Casson DH, et al. Retraction of an interpretation. Lancet 2004; 363:750.",
"     </a>",
"    </li>",
"    <li>",
"     Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism, Stratton K, Wilson CB, McCormick MC (Eds), The National Academies Press, Washington, DC 2001.",
"    </li>",
"    <li>",
"     Offit, PA. Vaccines and autism. Immunization Action Coalition. www.immunize.org/catg.d/p2065.htm (Accessed on January 18, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/31\">",
"      Fombonne E, Chakrabarti S. No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics 2001; 108:E58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/32\">",
"      Offit PA, Coffin SE. Communicating science to the public: MMR vaccine and autism. Vaccine 2003; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/33\">",
"      Taylor B, Miller E, Lingam R, et al. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 2002; 324:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/34\">",
"      Evans AS. Causation and disease: a chronological journey. The Thomas Parran Lecture. 1978. Am J Epidemiol 1995; 142:1126.",
"     </a>",
"    </li>",
"    <li>",
"     Immunization Safety Review: Vaccines and Autism. A report of the Institute of Medicine., The National Academies Press, Washington, DC 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/36\">",
"      Kawashima H, Mori T, Kashiwagi Y, et al. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. Dig Dis Sci 2000; 45:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/37\">",
"      Fernell E, Fagerberg UL, Hellstr&ouml;m PM. No evidence for a clear link between active intestinal inflammation and autism based on analyses of faecal calprotectin and rectal nitric oxide. Acta Paediatr 2007; 96:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/38\">",
"      Bitnun A, Shannon P, Durward A, et al. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 1999; 29:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/39\">",
"      McQuaid S, Cosby SL, Koffi K, et al. Distribution of measles virus in the central nervous system of HIV-seropositive children. Acta Neuropathol 1998; 96:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/40\">",
"      Martin CM, Uhlmann V, Killalea A, et al. Detection of measles virus in children with ileo-colonic lymphoid nodular hyperplasia, enterocolitis and developmental disorder. Mol Psychiatry 2002; 7 Suppl 2:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/41\">",
"      Afzal MA, Ozoemena LC, O'Hare A, et al. Absence of detectable measles virus genome sequence in blood of autistic children who have had their MMR vaccination during the routine childhood immunization schedule of UK. J Med Virol 2006; 78:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/42\">",
"      D'Souza Y, Fombonne E, Ward BJ. No evidence of persisting measles virus in peripheral blood mononuclear cells from children with autism spectrum disorder. Pediatrics 2006; 118:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/43\">",
"      Katz SL. Has the measles-mumps-rubella vaccine been fully exonerated? Pediatrics 2006; 118:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/44\">",
"      Hornig M, Briese T, Buie T, et al. Lack of association between measles virus vaccine and autism with enteropathy: a case-control study. PLoS One 2008; 3:e3140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/45\">",
"      Cass H, Gringras P, March J, et al. Absence of urinary opioid peptides in children with autism. Arch Dis Child 2008; 93:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/46\">",
"      Nagamitsu S, Matsuishi T, Kisa T, et al. CSF beta-endorphin levels in patients with infantile autism. J Autism Dev Disord 1997; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/47\">",
"      Gillberg C, Terenius L, L&ouml;nnerholm G. Endorphin activity in childhood psychosis. Spinal fluid levels in 24 cases. Arch Gen Psychiatry 1985; 42:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/48\">",
"      Gillberg C, Terenius L, Hagberg B, et al. CSF beta-endorphins in childhood neuropsychiatric disorders. Brain Dev 1990; 12:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/49\">",
"      Feldman HM, Kolmen BK, Gonzaga AM. Naltrexone and communication skills in young children with autism. J Am Acad Child Adolesc Psychiatry 1999; 38:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/50\">",
"      Willemsen-Swinkels SH, Buitelaar JK, van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry 1996; 39:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/51\">",
"      Willemsen-Swinkels SH, Buitelaar JK, Weijnen FG, van Engeland H. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res 1995; 58:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/52\">",
"      Baird G, Pickles A, Simonoff E, et al. Measles vaccination and antibody response in autism spectrum disorders. Arch Dis Child 2008; 93:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/53\">",
"      Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol 1979; 110:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/54\">",
"      Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/55\">",
"      Miller E, Waight P, Farrington CP, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001; 84:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/56\">",
"      Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999; 353:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/57\">",
"      DeStefano F, Bhasin TK, Thompson WW, et al. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan atlanta. Pediatrics 2004; 113:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/58\">",
"      M&auml;kel&auml; A, Nuorti JP, Peltola H. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 2002; 110:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/59\">",
"      Patja A, Davidkin I, Kurki T, et al. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. Pediatr Infect Dis J 2000; 19:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/60\">",
"      Peltola H, Patja A, Leinikki P, et al. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study. Lancet 1998; 351:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/61\">",
"      Smeeth L, Cook C, Fombonne E, et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet 2004; 364:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/62\">",
"      Fombonne E, Zakarian R, Bennett A, et al. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 2006; 118:e139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/63\">",
"      Mrozek-Budzyn D, Kietyka A, Majewska R. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatr Infect Dis J 2010; 29:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/64\">",
"      Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. J Child Psychol Psychiatry 2005; 46:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/65\">",
"      Wilson K, Mills E, Ross C, et al. Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence. Arch Pediatr Adolesc Med 2003; 157:628.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine of the National Academies. Measles, mumps, and rubella vaccine. In: Adverse Effects of Vaccines: Evidence and Causality, Stratton K, Ford A, Rusch E, Wright E.  (Eds), National Academies Press, Washington, DC 2011. p.89.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/67\">",
"      Farrington CP, Miller E, Taylor B. MMR and autism: further evidence against a causal association. Vaccine 2001; 19:3632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/68\">",
"      DeStefano F, Mullooly JP, Okoro CA, et al. Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. Pediatrics 2001; 108:E112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/69\">",
"      Infections and vaccinations as risk factors for childhood type I (insulin-dependent) diabetes mellitus: a multicentre case-control investigation. EURODIAB Substudy 2 Study Group. Diabetologia 2000; 43:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/70\">",
"      Heijbel H, Chen RT, Dahlquist G. Cumulative incidence of childhood-onset IDDM is unaffected by pertussis immunization. Diabetes Care 1997; 20:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/71\">",
"      Karvonen M, Cepaitis Z, Tuomilehto J. Association between type 1 diabetes and Haemophilus influenzae type b vaccination: birth cohort study. BMJ 1999; 318:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/72\">",
"      Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Childhood vaccination and type 1 diabetes. N Engl J Med 2004; 350:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/73\">",
"      Graves PM, Barriga KJ, Norris JM, et al. Lack of association between early childhood immunizations and beta-cell autoimmunity. Diabetes Care 1999; 22:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/74\">",
"      Blom L, Nystr&ouml;m L, Dahlquist G. The Swedish childhood diabetes study. Vaccinations and infections as risk determinants for diabetes in childhood. Diabetologia 1991; 34:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/75\">",
"      Hy&ouml;ty H, Hiltunen M, Reunanen A, et al. Decline of mumps antibodies in type 1 (insulin-dependent) diabetic children and a plateau in the rising incidence of type 1 diabetes after introduction of the mumps-measles-rubella vaccine in Finland. Childhood Diabetes in Finland Study Group. Diabetologia 1993; 36:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/76\">",
"      Levitsky LL. Childhood immunizations and chronic illness. N Engl J Med 2004; 350:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/77\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children--United States, 1998-2000. MMWR Morb Mortal Wkly Rep 2002; 51:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/78\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward eliminating Haemophilus influenzae type b disease among infants and children--United States, 1987-1997. MMWR Morb Mortal Wkly Rep 1998; 47:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/79\">",
"      Smith MJ, Ellenberg SS, Bell LM, Rubin DM. Media coverage of the measles-mumps-rubella vaccine and autism controversy and its relationship to MMR immunization rates in the United States. Pediatrics 2008; 121:e836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/80\">",
"      The measles epidemic. The problems, barriers, and recommendations. The National Vaccine Advisory Committee. JAMA 1991; 266:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/81\">",
"      Feikin DR, Lezotte DC, Hamman RF, et al. Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA 2000; 284:3145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/82\">",
"      White CC, Koplan JP, Orenstein WA. Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health 1985; 75:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/83\">",
"      Gangarosa EJ, Galazka AM, Wolfe CR, et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 1998; 351:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/84\">",
"      Friederichs V, Cameron JC, Robertson C. Impact of adverse publicity on MMR vaccine uptake: a population based analysis of vaccine uptake records for one million children, born 1987-2004. Arch Dis Child 2006; 91:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/85\">",
"      Johnson RT, Griffin DE, Hirsch RL, et al. Measles encephalomyelitis--clinical and immunologic studies. N Engl J Med 1984; 310:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/86\">",
"      Weibel RE, Caserta V, Benor DE, Evans G. Acute encephalopathy followed by permanent brain injury or death associated with further attenuated measles vaccines: a review of claims submitted to the National Vaccine Injury Compensation Program. Pediatrics 1998; 101:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26857/abstract/87\">",
"      Roos RP, Graves MC, Wollmann RL, et al. Immunologic and virologic studies of measles inclusion body encephalitis in an immunosuppressed host: the relationship to subacute sclerosing panencephalitis. Neurology 1981; 31:1263.",
"     </a>",
"    </li>",
"    <li>",
"     Brooks GF, Butel JS, Morse SA. Paramyxoviruses and rubella virus. In: Jawetz, Melnick, &amp; Adelberg's Medical Microbiology, 21st, Butler JP, Ransom J, Ryan E (Eds), Appleton &amp; Lange, Stamford, CT 1998. p.50.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2861 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-B2700F0D78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_14_26857=[""].join("\n");
var outline_f26_14_26857=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPARENT INCREASE IN AUTISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      POSSIBLE ASSOCIATION BETWEEN AUTISM AND MMR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Enterocolitis and regression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Persistent intestinal measles virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LACK OF EVIDENCE FOR ASSOCIATION BETWEEN AUTISM AND MMR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Biologic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Epidemiologic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OTHER CHRONIC DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROVEN BENEFITS OF VACCINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15594403\">",
"      OUTSIDE SOURCES OF PATIENT EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21066?source=related_link\">",
"      Autism and chronic disease: Little evidence for thimerosal as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=related_link\">",
"      Clinical features of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=related_link\">",
"      Clinical presentation and diagnosis of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=related_link\">",
"      Diagnosis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41608?source=related_link\">",
"      Microbiology, epidemiology and treatment of Haemophilus influenzae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23210?source=related_link\">",
"      Pathogenesis of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/46/41699?source=related_link\">",
"      Patient information: Autism spectrum disorders (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=related_link\">",
"      Poliovirus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=related_link\">",
"      Terminology, epidemiology, and pathogenesis of autism spectrum disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_14_26858="Monomorphic ventricular tachycardia in the absence of apparent structural heart disease";
var content_f26_14_26858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/14/26858/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/14/26858/contributors\">",
"     David J Callans, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/14/26858/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/14/26858/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/14/26858/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/14/26858/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/14/26858/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation and management of ventricular tachyarrhythmias are uniquely challenging due to the unpredictable and potentially lethal nature of the events. When evaluating patients with ventricular tachycardia (VT) and ventricular fibrillation (VF), several initial distinctions should be made. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arrhythmia duration &ndash; sustained or nonsustained",
"     </li>",
"     <li>",
"      Arrhythmia morphology &ndash; monomorphic VT, polymorphic VT, or VF",
"     </li>",
"     <li>",
"      Associated symptoms &ndash; ranging from none to hemodynamic collapse and sudden cardiac arrest",
"     </li>",
"     <li>",
"      Associated cardiac disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Malignant arrhythmias usually occur in the presence of significant structural heart disease (eg, coronary heart disease with prior myocardial infarction, dilated cardiomyopathy, or hypertrophic cardiomyopathy). In this setting, ventricular arrhythmias carry a high risk of sudden cardiac death (SCD).",
"   </p>",
"   <p>",
"    Less commonly, VT and VF occur in hearts that appear normal. In many such cases, however, the heart is in fact not normal, but rather has less visible abnormalities including derangements of cardiac ion channels or structural proteins. In these patients, ventricular arrhythmias also carry a high risk of SCD. Thus, a significant majority of patients with VT or VF have some form of underlying cardiac disease, are at increased risk for SCD, and require a thorough cardiac evaluation to exclude structural abnormalities and nonstructural disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=see_link\">",
"     \"Evaluation of the survivor of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, some VT syndromes which occur in normal hearts that have a more benign prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These arrhythmias are sometimes referred to as idiopathic VT. Terminology and classifications vary, but three commonly cited syndromes are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repetitive monomorphic VT, which is also referred to as right ventricular outflow tract (RVOT) VT. This arrhythmia is due to triggered activity and is sensitive to adenosine. An arrhythmia with similar characteristics that originates from the left ventricular outflow tract has also been described.",
"     </li>",
"     <li>",
"      Paroxysmal sustained VT, which is sometimes considered a variant of RVOT VT.",
"     </li>",
"     <li>",
"      Idiopathic left ventricular tachycardia, which originates from the posterior septum, is due to reentry, and is sensitive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These arrhythmias have substrate and mechanisms that are different from the malignant arrhythmias that occur in both abnormal and apparently normal hearts. Thus, they should be considered distinct syndromes rather than well-tolerated forms of other ventricular arrhythmia syndromes. The diagnosis, characterization, and management of these monomorphic VTs will be reviewed here.",
"   </p>",
"   <p>",
"    Sustained and nonsustained ventricular arrhythmias in patients with heart disease, and malignant ventricular arrhythmias in the absence of apparent structural heart disease are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39702?source=see_link\">",
"     \"Prognosis of nonsustained VT in the presence of structural heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link\">",
"     \"Sudden cardiac arrest in the absence of apparent structural heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13974?source=see_link\">",
"     \"Nonsustained VT in the absence of apparent structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IDIOPATHIC VENTRICULAR ARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the term idiopathic VT is widely used for the monomorphic VT syndromes described here, use of \"idiopathic\" can be misleading. Historically, both VT and VF that occur in the absence of apparent heart disease have been referred to as idiopathic. However, with continual improvements in both the understanding of arrhythmia mechanisms and diagnostic methods, an increasing percentage of patients are now given a diagnosis (eg, Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy [ARVC], and catecholaminergic polymorphic VT). In contrast to the syndromes discussed here, these disorders have an increased risk of sudden cardiac death (SCD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link\">",
"     \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link&amp;anchor=H1492612#H1492612\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Ventricular arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Previously reported series of idiopathic VT and VF are likely to include a heterogeneous group of patients with various diagnoses and prognoses. Currently, idiopathic VT generally refers to one of the three benign syndromes described here and excludes patients with other diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12026071\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple classification schemata for idiopathic VT appear in the literature. Investigations of idiopathic VT syndromes have focused for the most part on individual aspects of the syndrome (eg, clinical presentation, electrocardiographic appearance, electrophysiologic mechanism, response to antiarrhythmic agents); this approach has yielded a bewildering amount of often conflicting information. Despite this confusion, most investigators acknowledge the existence of at least three syndromes of idiopathic monomorphic VT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repetitive monomorphic VT, also called right ventricular outflow tract (RVOT) VT, is a triggered arrhythmia that is characterized by frequent short \"salvos\" of nonsustained VT. Less commonly, arrhythmias with similar characteristics and mechanisms originate from the LVOT, and these are considered a variant of RVOT VT.",
"     </li>",
"     <li>",
"      Paroxysmal sustained VT, which also arises from the RV, and is sometimes considered a sustained variant of repetitive monomorphic VT.",
"     </li>",
"     <li>",
"      Idiopathic left ventricular tachycardia, which differs from the LVOT variant of RVOT VT in both the mechanism (reentry) and site of origin (inferoapex or midseptum).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These three syndromes effectively characterize the majority of patients with idiopathic monomorphic VT and often unite clinical presentation, ECG morphology, and anatomic location into recognizable syndromes (",
"    <a class=\"graphic graphic_table graphicRef54842 \" href=\"UTD.htm?43/27/44476\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bundle branch reentrant VT is a special form of monomorphic VT that typically occurs in patients with structural heart disease. Patients with BBRVT often have a baseline nonspecific conduction delay or left bundle branch block, and most have a prolonged His-to-ventricle time (ie, HV interval). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41637?source=see_link\">",
"     \"Bundle branch reentrant ventricular tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Idiopathic VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic VT has accounted for approximately 10 percent all patients referred for evaluation of VT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/1\">",
"     1",
"    </a>",
"    ]. The mean age of patients with idiopathic VT is less than that of patients with VT secondary to underlying heart disease.",
"   </p>",
"   <p>",
"    It is important to recognize that not all VT that occurs in the apparent absence of structural heart disease is idiopathic VT. Distinguishing idiopathic VT from other monomorphic VT syndromes is important for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiopathic VT is generally considered to have an excellent prognosis in terms of freedom from both the development of structural heart disease and arrhythmic death [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/3-9\">",
"       3-9",
"      </a>",
"      ]. There are several exceptions to this generalization, however, and episodes of SCD can occur [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Idiopathic VT often responds to antiarrhythmic drugs that would be unhelpful or even contraindicated in VT occurring in the setting of coronary heart disease.",
"     </li>",
"     <li>",
"      Most idiopathic VT syndromes are now amenable to cure with catheter ablation techniques.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Other ventricular tachyarrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to monomorphic VT, both polymorphic VT and VF can occur in the absence of structural heart disease. In contrast to the generally good prognosis associated with idiopathic monomorphic VT, these syndromes are associated with an increased risk of SCD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link\">",
"     \"Sudden cardiac arrest in the absence of apparent structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polymorphic VT in the absence of structural heart disease occurs in two settings: with a prolonged QT interval in acquired or inherited long QT syndrome; and with a normal QT interval in usually familial disease, which is also called catecholaminergic polymorphic VT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"       \"Clinical features of congenital long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link\">",
"       \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      VF in the absence of structural heart disease or other reversible arrhythmic triggers (eg, ischemia or metabolic derangements) is also referred to as idiopathic. The diagnosis of idiopathic VF is considered only after all other causes of VF have been rigorously excluded. The rationale for this approach comes from autopsy studies of SCD in previously healthy individuals. These studies found an appreciable incidence of coronary heart disease (most without a previous history of chest pain), hypertrophic cardiomyopathy, myocarditis, and ARVC. Brugada syndrome is a specific cause of lethal ventricular arrhythmias in patients without structural heart disease; it is characterized by ST elevation in the anterior precordial leads on the resting surface electrocardiogram. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link&amp;anchor=H11#H11\">",
"       \"Sudden cardiac arrest in the absence of apparent structural heart disease\", section on 'Idiopathic VF'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"       \"Brugada syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, patients with idiopathic monomorphic VT have no detectable structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. Thus, the assessment of these patients focuses upon establishing the presence of a normal heart. The evaluation of the patient with sustained ventricular arrhythmias and sudden death is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43144?source=see_link&amp;anchor=H10017877#H10017877\">",
"     \"Sustained monomorphic ventricular tachycardia: Diagnosis and evaluation\", section on 'Diagnostic evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=see_link\">",
"     \"Evaluation of the survivor of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the purposes of this review, the following summarizes findings that may be seen in patients with idiopathic monomorphic VT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The resting ECG is typically normal between arrhythmia episodes, although some patients have temporary ECG repolarization abnormalities immediately after VT termination.",
"     </li>",
"     <li>",
"      The signal averaged ECG recorded during sinus rhythm is usually normal, although abnormalities may be seen during VT [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/5,10\">",
"       5,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Functional studies of left ventricular (LV) and right ventricular (RV) performance during sinus rhythm are normal, although segmental wall motion abnormalities may be seen immediately after VT termination. In patients who have not had a recent episode of VT, abnormalities in ventricular function should suggest an alternative diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=see_link&amp;anchor=H13#H13\">",
"       \"Evaluation of the survivor of sudden cardiac arrest\", section on 'Echocardiography'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      However, in rare cases, LV dysfunction can occur as a consequence of idiopathic VT, due to a tachycardia-induced cardiomyopathy. Such a myopathy can develop without persistent tachycardia if there are very frequent PVCs (ie, &gt;20,000 per day) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/11\">",
"       11",
"      </a>",
"      ]. This is a very important condition to recognize, as the LV dysfunction is reversible with treatment of the arrhythmia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link&amp;anchor=H14#H14\">",
"       \"Tachycardia-mediated cardiomyopathy\", section on 'Frequent ventricular ectopy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The exercise stress test should be normal. Coronary angiography, which is considered in patients with minimally symptomatic arrhythmias only if the stress test suggests ischemia, should also be normal.",
"     </li>",
"     <li>",
"      Cardiovascular magnetic resonance imaging (CMR) may reveal mild structural abnormalities of the RV in patients with RMVT, primarily involving the free wall (focal thinning, fatty infiltration, and wall motion abnormalities) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. The significance of these changes is unclear, since there is a poor correlation between the origin of the RMVT and the site of the CMR abnormalities unless they are also present in the RVOT.",
"     </li>",
"     <li>",
"      Limited data suggest that RV radionuclide myocardial perfusion imaging can distinguish between idiopathic monomorphic VT and VT due to an organic cause such as dilated cardiomyopathy, myocarditis, or ARVC [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      RV biopsy, which is rarely performed, is usually normal, although a number of studies have reported abnormalities that are nonspecific and of no significant value [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/16-18\">",
"       16-18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Distinction from ARVC",
"    </span>",
"    &nbsp;&mdash;&nbsp;RMVT can be particularly difficult to distinguish from the more serious disorder, ARVC. Although ARVC is unlikely in patients who have a normal signal averaged electrocardiogram and normal imaging studies of RV size and function, the \"development\" of ARVC in patients thought to have idiopathic VT at presentation has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/8,19\">",
"     8,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link&amp;anchor=H29#H29\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\", section on 'RVOT tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the clinical boundaries between idiopathic RV tachycardia and ARVC may be difficult to establish in atypical cases. The findings on the ECG, signal averaged ECG, and electrophysiology (EP) studies may be helpful in making this distinction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The resting ECG can be normal at presentation in approximately 40 percent of patients with ARVC. However, characteristic abnormalities of ARVC develop in almost all patients within six years of presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/20\">",
"       20",
"      </a>",
"      ]. In a cohort of 59 patients (17 with ARVC, 42 with RMVT), ECG features suggestive of ARVC included longer mean QRS duration in lead I (150 versus 123 msec in RMVT), precordial transition in lead V6 (18 versus 0 percent in RMVT), and at least one lead with QRS notching (65 versus 21 percent in RMVT) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The signal averaged ECG in the time domain is typically abnormal in ARVC, but usually normal in idiopathic RV tachycardia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On EP study, four findings are seen in most patients with ARVC but are rare in idiopathic RV tachycardia: inducible VT by programmed stimulation; multiple VT morphologies; fractionated diastolic electrograms during VT or sinus rhythm at the VT site of origin or other RV sites; and regions of low amplitude and prolonged duration on intracardiac electrograms [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/22-24\">",
"       22-24",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Electrophysiologic features'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     REPETITIVE MONOMORPHIC VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive monomorphic VT (RMVT) is characterized by frequent short \"salvos\" of monomorphic nonsustained VT (",
"    <a class=\"graphic graphic_waveform graphicRef66679 \" href=\"UTD.htm?31/21/32088\">",
"     waveform 1",
"    </a>",
"    ). It was first described by Gallavardin in 1922 and is variously described in the literature as RMVT, RV tachycardia, RVOT tachycardia, catecholamine-sensitive VT, adenosine-sensitive VT, and exercise-induced VT. Approximately 10 to 15 percent of cases arise from the left ventricular outflow tract [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although RMVT is considered to occur in \"normal\" hearts, static and cine-magnetic resonance imaging often reveal mild structural abnormalities of the RV, primarily involving the free wall (focal thinning, fatty infiltration, and wall motion abnormalities) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. The functional significance of these changes is uncertain. In the few cases studied, DNA from myocardial biopsies of ventricular muscle has been normal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Epidemiology and clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;RMVT occurs almost exclusively in young to middle-aged patients without structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. There has generally been no predilection on the basis of sex, although a 2:1 female predominance was observed in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/25\">",
"     25",
"    </a>",
"    ]. A surprising number of competitive athletes (particularly cyclists) are identified in many series of RMVT.",
"   </p>",
"   <p>",
"    The most common associated symptoms are palpitations and lightheadedness during episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In one illustrative report of 18 patients, twelve had symptomatic arrhythmia, two of whom had syncope, and six were completely asymptomatic.",
"   </p>",
"   <p>",
"    Most arrhythmias are nonsustained (usually 3 to 15 beats), but up to one-half of patients have some sustained episodes, and some patients have only sustained VT (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Paroxysmal sustained VT'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/5,8,12,29\">",
"     5,8,12,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bursts of nonsustained VT are typically provoked by emotional stress or exercise, often occurring during the \"warm-down\" period after exercise, a time when circulating catecholamines are at peak levels [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/4,5,7\">",
"     4,5,7",
"    </a>",
"    ]. There may also be a circadian pattern, with prominent peaks between 7 and 11 AM and 4 and 8 PM, correlating with periods of increased sympathetic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/30\">",
"     30",
"    </a>",
"    ]. In some patients, a critical \"window\" of heart rates (upper and lower thresholds) that result in occurrence of the arrhythmia can be defined [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inducibility of RMVT by stress or catecholamine infusion is suggestive of an abnormality in cardiac sympathetic function. Consistent with this hypothesis is evidence of regional cardiac sympathetic denervation in some patients with RMVT and structurally normal hearts (five of nine compared to zero of nine controls in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients with RMVT may also have regions of impaired neuronal reuptake of norepinephrine, leading to increased local synaptic catecholamine concentrations and downregulation of myocardial beta adrenergic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may also be sex-specific triggers. In a report of 47 men and women with RMVT, states of hormonal flux (premenstrual, gestational, perimenopausal, administration of birth control pills) were the most common trigger for RMVT in 59 percent of women and were the only recognizable triggers in 41 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/33\">",
"     33",
"    </a>",
"    ]. Men were more likely than women to identify exercise, stress, or caffeine as a trigger (92 versus 41 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Site of origin",
"    </span>",
"    &nbsp;&mdash;&nbsp;RV tachycardias usually originate from the septal aspect of the RVOT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/5,25,27,34-37\">",
"     5,25,27,34-37",
"    </a>",
"    ]. A nine site mapping schema of the septal RVOT has proven useful in localizing RVOT tachycardias on the basis of their 12 lead ECG morphology (",
"    <a class=\"graphic graphic_figure graphicRef72301 \" href=\"UTD.htm?43/45/44767\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RV tachycardias typically arise from a very narrow area just inferior to the pulmonary valve in the anterior aspect of the RVOT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/36\">",
"     36",
"    </a>",
"    ]. Endocardial mapping in such patients shows that the earliest site of endocardial activation occurs in this region [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/5,8\">",
"     5,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less commonly, sites of origin have been mapped to the RV inflow tract, the free wall of the RVOT, the root of the pulmonary artery, the left and right aortic sinus of Valsalva, the left ventricle, the mitral annulus, and the papillary muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/25,35,37,39-48\">",
"     25,35,37,39-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Electrocardiographic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical rate of RMVT ranges from 140 to 180",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    and may fluctuate based upon catecholamine levels. The VT cycle length often prolongs prior to termination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     RVOT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of RMVT episodes have a characteristic ECG appearance with two main features [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/1-8,38\">",
"     1-8,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Left bundle branch block",
"     </li>",
"     <li>",
"      Inferior axis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This morphology is consistent with the RVOT origin seen by catheter ablation and endocardial mapping [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/5,36\">",
"     5,36",
"    </a>",
"    ]. This ECG \"signature\" accounts for at least 70 percent of all idiopathic VTs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ECG pattern of RV tachycardia initiation may provide information about the site of origin and the arrhythmogenic mechanism as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 32 patients with exercise-induced RMVT, VT usually began without a change in cycle length. Arrhythmias that initiated in this manner had an inferior axis, and appeared to be related to triggered activity due to delayed afterpotentials [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/49\">",
"       49",
"      </a>",
"      ]. In comparison, VT initiated with a long-short sequence was more often nonsustained and often had a superior axis, suggesting an origin in the body or septal region of the ventricle; the mechanism for this VT is probably early afterpotentials.",
"     </li>",
"     <li>",
"      In a report of 14 patients, those with septal compared to free wall sites were significantly less likely to have notching of the QRS complex (29 versus 95 percent) and more likely to show early precordial transition by lead V4 (79 versus 5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/50\">",
"       50",
"      </a>",
"      ]. In addition, a positive R wave in lead I distinguished posterior from anterior septal and free wall sites.",
"     </li>",
"     <li>",
"      The degree of similarity of 12-lead ECG waveforms between VT and a pace map can be used to estimate the likelihood of successful ablation at that site. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Radiofrequency ablation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of patients with RV tachycardia have a single ECG morphology [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/22\">",
"     22",
"    </a>",
"    ]. However, occasional patients present with multiple tachycardia morphologies arising from discrete sites in the RVOT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/51\">",
"     51",
"    </a>",
"    ]. The presence of multiple left bundle VT morphologies, particularly during EP study, should suggest the possibility of ARVC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/22,52,53\">",
"     22,52,53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Distinction from ARVC'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     LV outflow tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocardiographic criteria have also been described for RMVT originating in the LVOT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In a series of 33 patients with RMVT, four (12 percent) had LV sites of origin that could be predicted by two patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A right bundle, inferior axis morphology with a monophasic R wave in V1 that arose from the left fibrous trigone (",
"      <a class=\"graphic graphic_waveform graphicRef81690 \" href=\"UTD.htm?9/6/9318\">",
"       waveform 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A pattern similar to typical RMVT from the RVOT (left bundle, inferior axis) except that the precordial transition was earlier (at V2 for the LVOT as compared to V3 or later for the RVOT)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other reports have characterized unique QRS morphologies for idiopathic VT arising from the sinuses of Valsalva [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/8,42,43\">",
"     8,42,43",
"    </a>",
"    ]. Although there is some interindividual variability, ventricular premature complexes arising from the left aortic sinus tend to be negative in lead I and have a \"w\" pattern in V1, while ventricular premature complexes with a broad R wave in V1 is characteristic of a right aortic cusp origin. The precordial R wave transition is much earlier when VT originates from either aortic sinus of Valsalva compared to the RVOT, since the LVOT is posterior to the RVOT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Electrophysiologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;RMVT can be induced in the EP laboratory, although usually not with programmed stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/4,5,22,26,54\">",
"     4,5,22,26,54",
"    </a>",
"    ]. In most patients, sustained or nonsustained episodes occur in response to burst atrial or ventricular pacing, and are greatly facilitated by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    or epinephrine infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/4,5,26,29,54\">",
"     4,5,26,29,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These electrophysiologic observations suggest that triggered activity due to delayed afterpotentials, rather than reentry, is the mechanism of RMVT. The response to \"pharmacologic probes\" further strengthens this hypothesis. RMVT has been terminated with adenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , and beta blockers, all of which interfere with the cAMP-mediated slow inward calcium current [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/28,39,55-57\">",
"     28,39,55-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations are consistent with the hypothesis that RMVT results from triggered activity induced by cAMP-mediated delayed after depolarizations (DADs) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/29,58\">",
"     29,58",
"    </a>",
"    ]. The increase in cAMP activity may, at least in some patients, result from an acquired somatic cell mutation in the inhibitory G protein G-alpha-i2 at the site of the arrhythmogenic focus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the lack of specificity of these probes and the absence of a uniform response supports the general consensus that the mechanism of RMVT is incompletely characterized and may vary among individuals. Additional support for other mechanisms is based upon the observation that the tachycardia may, in some patients, terminate with overdrive pacing, ventricular extrastimulation, or autonomic modulation using Valsalva maneuver or carotid sinus pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EP studies may also help distinguish RMVT occurring in the absence of structural heart disease from that in ARVC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Distinction from ARVC'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of RMVT is almost uniformly good [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/3-8,54\">",
"     3-8,54",
"    </a>",
"    ]. The following observations from early studies illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two initial series evaluated 30 and 18 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. The arrhythmia responded to a variety of antiarrhythmic drugs, including type I drugs and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      . At a mean of 30 months in one study and a range of 0.5 to 8 years in the other, there were no deaths or episodes of cardiac arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third report consisted of 24 young patients, most of whom had RV tachycardia and two-thirds of whom were symptomatic [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/6\">",
"       6",
"      </a>",
"      ]. At a mean follow-up of 7.5 years, three patients died suddenly; none was taking antiarrhythmic drugs at the time. The SCD events may have been due to RMVT itself, although patients with other syndromes now known to be malignant may have been included (eg, Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy). Alternatively, a tachycardia-induced cardiomyopathy may have predisposed patients to additional arrhythmias. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"       \"Tachycardia-mediated cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Malignant variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;More recent studies in which these other syndromes were unlikely have identified a malignant variant of RMVT. Polymorphic VT and VF, which are malignant arrhythmias, have been demonstrated in patients with RMVT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. In one series, three patients with RMVT later developed VF. In these patients, VPBs were more closely coupled to prior beats than is usual for RMVT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/60\">",
"     60",
"    </a>",
"    ]. It was postulated that relatively early triggered beats occurred in a vulnerable period during repolarization, resulting in VF.",
"   </p>",
"   <p>",
"    In a subsequent report, 16 patients with frequent VPBs from the RVOT were noted to have polymorphic VT or VF that was initiated by one of the VPBs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/61\">",
"     61",
"    </a>",
"    ]. In contrast to the first study, the coupling interval of the VPBs in patients who developed malignant arrhythmias was not different from that in 85 other patients with RMVT who did not have malignant arrhythmias. Radiofrequency (RF) ablation successfully eliminated the RVOT VPBs in 13 patients and modified the VPBs in the other three. Over a mean follow-up of 54 months, none had recurrent VF or syncope. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Radiofrequency ablation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The prevalence of this malignant variant, and whether it represents a distinct disorder from RMVT, is unclear. The high frequency in the above study (16 of 101 patients) is probably a substantial overestimate due to referral bias. In addition, it is possible that some cases categorized as polymorphic VT were simply the common form of RVOT VT in which QRS morphology varied during the tachycardia due to fluctuations in loading conditions. An editorial accompanying this report addressed the issue of whether RF ablation should now be considered in all patients with RMVT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/62\">",
"     62",
"    </a>",
"    ]. Due to the relatively high prevalence of RVOT VPBs, the rarity of malignant RVOT",
"    <span class=\"nowrap\">",
"     VT/VF,",
"    </span>",
"    it is reasonable to focus concern on patients with the following higher risk characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A history of syncope",
"     </li>",
"     <li>",
"      Very fast VT (&gt;230",
"      <span class=\"nowrap\">",
"       beats/min)",
"      </span>",
"     </li>",
"     <li>",
"      Very frequent ectopy (&gt;20,000",
"      <span class=\"nowrap\">",
"       VPBs/day)",
"      </span>",
"     </li>",
"     <li>",
"      VPBs with a short coupling interval",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment of RMVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic decisions for RMVT should consider that many patients are young and otherwise healthy. As a result, ablative therapy may be preferable to chronic administration of antiarrhythmic drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapy serves two roles in RMVT: termination of the arrhythmia; and prevention of recurrence. RMVT can be terminated with adenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , and beta blockers, all of which interfere with the cAMP-mediated slow inward calcium current [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/28,39,55-57\">",
"     28,39,55-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For prevention of recurrence,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and beta blockers are often used as first-line agents. These drugs are attractive since their side effect profiles are mild in comparison to antiarrhythmic agents.",
"   </p>",
"   <p>",
"    The success rate in clinical studies has been variable.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    has achieved a therapeutic success rate as high as 67 percent in patients with a typical RVOT origin of RMVT, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    has prevented recurrence in as many as 14 of 22 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/5,63\">",
"     5,63",
"    </a>",
"    ]. However, other studies have found that these agents were much less likely to prevent recurrent RMVT, although the combination of a beta blocker with a class I drug may be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/8,54\">",
"     8,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Class I antiarrhythmic agents (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 2",
"    </a>",
"    ) alone are helpful in some patients. However, class III drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ) may be preferred, especially in patients with arrhythmia that is refractory to other drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the limited efficacy and potential side effects of antiarrhythmic drugs, there has been increasing use of radiofrequency (RF) ablation in patients with symptomatic RMVT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Success rates for RF catheter ablation range from 80 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/27,34,35,39,40,64\">",
"     27,34,35,39,40,64",
"    </a>",
"    ]. The success rate depends in part upon the location of the focus; the success of catheter ablation for idiopathic VTs in atypical positions is generally not as high as for RVOT locations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/35\">",
"     35",
"    </a>",
"    ]. The degree of similarity of 12-lead ECG waveforms between VT and a pace map can be used to estimate the likelihood of successful ablation at that site [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/65\">",
"     65",
"    </a>",
"    ]. A mean absolute deviation &gt;12 percent suggests sufficient dissimilarity to dissuade ablation at that site.",
"   </p>",
"   <p>",
"    Although successful ablation of LVOT tachycardia has been performed using an endocardial approach, coronary venous mapping and percutaneous approaches to the pericardial space have shown that some of these VTs arise from the LV epicardium [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/27,44,45,64,66\">",
"     27,44,45,64,66",
"    </a>",
"    ]. There have also been several reports of successful ablation of RMVT from the left and right sinuses of Valsalva [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiofrequency ablation is generally associated with a low rate of procedural complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/27,34-37,39\">",
"     27,34-37,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link&amp;anchor=H22#H22\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long term follow-up of patients successfully treated with radiofrequency catheter ablation is limited. In two reports of 42 patients in whom all tachycardias were successfully ablated, only five (12 percent) had a detected recurrence during a 2 to 50 month follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/64,67\">",
"     64,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of successful ablation may be less when the site of origin is not endocardial or not definitively identified during mapping [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/64\">",
"     64",
"    </a>",
"    ]. In a review of 75 patients with presumed RVOT VT, the inability to identify a focus, and therefore the success rate, correlated with the QRS duration in lead V2 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/68\">",
"     68",
"    </a>",
"    ]. The success rate was 95 percent when the QRS duration in V2 during pace mapping was &ge;160 ms in duration compared to only 54 percent when the QRS duration was &lt;160 ms. Left-sided and epicardial ablation strategies were not pursued in this experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29141861\">",
"    <span class=\"h4\">",
"     Epicardial ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible explanation for failed radiofrequency ablation is that the arrhythmia arises from an epicardial rather than an endocardial focus. In one report of failed ablation (either acute failure of the procedure or late recurrence of arrhythmia) in 30 patients with VT (15 with apparently normal hearts), subxiphoid instrumentation of the pericardial space was used for both epicardial mapping and ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/66\">",
"     66",
"    </a>",
"    ]. Twenty-four of the VTs appeared to originate from the epicardium; 17 were successfully ablated, while the other seven had sites that were inaccessible primarily due to interference from the left atrial appendage. Six of these seven patients could be ablated from the left coronary cusp.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PAROXYSMAL SUSTAINED VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal sustained VT is another clinical syndrome of idiopathic right ventricular tachycardia that resembles RMVT in many ways [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/5,8,12,69\">",
"     5,8,12,69",
"    </a>",
"    ]. The most frequent QRS morphology is a left bundle branch block with an inferior axis, and the typical site of origin is the superior septal aspect of the RVOT. Furthermore, patients with paroxysmal sustained VT appear to respond to antiarrhythmic agents, particularly adenosine, in a manner similar to patients with RMVT, although data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of these similarities, it is not clear if paroxysmal sustained VT is a distinct clinical syndrome. Compared to nonsustained RMVT, this disorder is more often symptomatic and less often exercise-provoked. It is also more frequently induced by programmed stimulation, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    may facilitate induction in some cases.",
"   </p>",
"   <p>",
"    On the other hand, some investigators dispute the existence of paroxysmal sustained VT as a syndrome distinct from RMVT. One study, for example, found that 58 percent of patients with RMVT had at least one episode of sustained VT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, electrophysiologic studies may reproduce sustained VT in patients who present with only nonsustained VT (particularly during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    infusion) or vice versa. It has also been suggested that the incidence of sudden cardiac death in RMVT is actually due to overlap with paroxysmal sustained VT. For these reasons, the two syndromes are occasionally considered together as idiopathic right ventricular tachycardia, or simply as RMVT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     IDIOPATHIC LEFT VENTRICULAR TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic left ventricular tachycardia (ILVT) was first described in 1979 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/70\">",
"     70",
"    </a>",
"    ]. Belhassen was the first to report the characteristic termination of this VT with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/71\">",
"     71",
"    </a>",
"    ], accounting for its two descriptive eponyms: Belhassen VT; and verapamil-responsive VT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical patient with ILVT presents at age 20 to 40, but often reports symptomatic episodes dating back to adolescence. The clinical characteristics of ILVT appear to be more uniform than those of the idiopathic RV tachycardias [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/9,71-76\">",
"     9,71-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It has a more variable association with physical activity, and is not usually provoked by exercise.",
"     </li>",
"     <li>",
"      It frequently produces symptoms such as palpitations and presyncope; syncope is uncommon.",
"     </li>",
"     <li>",
"      Cardiac arrest is rare, but isolated cases have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tachycardia-related cardiomyopathy has been reported, but is unusual since episodes are typically infrequent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Site of origin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocardial mapping during the VT demonstrates that the site of earliest activation is the inferoseptal region of the left ventricle in patients with a left frontal axis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/9\">",
"     9",
"    </a>",
"    ]. Mapping for catheter ablation also consistently localizes this VT to the inferior aspect of the midseptal region [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/77\">",
"     77",
"    </a>",
"    ]. In comparison, the anterosuperior left ventricle is the initial site in those patients with VT that has a right frontal axis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/9,74,78\">",
"     9,74,78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Electrocardiographic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corresponding to its left ventricular origin, ILVT has a right bundle branch block morphology with a left superior frontal plane axis and a relatively narrow QRS duration (typically 0.12 to 0.14 sec) (",
"    <a class=\"graphic graphic_waveform graphicRef64279 \" href=\"UTD.htm?10/2/10280\">",
"     waveform 3",
"    </a>",
"    ). A small subset of patients with ILVT has a right frontal plane (2 of 16 in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ILVT is often confused with supraventricular tachycardia because of its characteristic ECG morphology, and the response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    (see below). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The signal averaged ECG in the time domain is usually normal during sinus rhythm. However, frequency analysis using fast Fourier transform has shown an abnormal high-frequency component of the initial portion of the QRS complex that may distinguish these patients from normals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Electrophysiologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;ILVT is typically reproduced in the electrophysiology laboratory using programmed stimulation employing extrastimuli and, on occasion, with rapid atrial or ventricular pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/9,37,70-76\">",
"     9,37,70-76",
"    </a>",
"    ]. In contrast to RMVT, ILVT is not usually provoked by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    infusion.",
"   </p>",
"   <p>",
"    These observations, coupled with the response of ILVT to pacing (entrainment), support a reentrant mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/78\">",
"     78",
"    </a>",
"    ]. Further support for a reentrant mechanism comes from several mapping studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report identified a mid-diastolic potential and a single fused presystolic Purkinje potential at the VT exit site during VT [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/80\">",
"       80",
"      </a>",
"      ]. This observation suggests a macroreentry circuit involving the normal Purkinje system and abnormal Purkinje tissue that manifests decremental properties and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      sensitivity.",
"     </li>",
"     <li>",
"      A second study using electroanatomic mapping found that, during sinus rhythm, only patients with ILVT had a retrograde potential originating from the left posterior Purkinje fiber; diastolic potentials during ILVT coincided with the earliest retrograde Purkinje potential during sinus rhythm [",
"      <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The His bundle is commonly activated early in a retrograde fashion during ILVT, and a distinct Purkinje spike typically precedes the onset of the QRS (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51420 \" href=\"UTD.htm?1/59/1971\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/72\">",
"     72",
"    </a>",
"    ]. However, the retrograde His bundle deflection can be dissociated from the QRS complex by premature stimulation in the ventricle, atrium, or His region, implying that the reentrant circuit does not require the His bundle [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/74,76\">",
"     74,76",
"    </a>",
"    ]. These findings also suggest that the posterior fascicle of the left bundle branch may be a part of, or at least in close proximity to the VT circuit (",
"    <a class=\"graphic graphic_figure graphicRef68778 graphicRef76252 \" href=\"UTD.htm?3/8/3208\">",
"     figure 2A-B",
"    </a>",
"    ). The terms fascicular ventricular tachycardia and fascicular tachycardia been used to describe this arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/76,81,82\">",
"     76,81,82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Treatment of ILVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    is usually effective in the treatment of ILVT, both for the termination of acute episodes and the prevention of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/9,74-76,81\">",
"     9,74-76,81",
"    </a>",
"    ]. In one report, for example, intravenous verapamil terminated the arrhythmia in 13 of 14 patients and was effective in all five patients who required long-term oral therapy for symptom control [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/9\">",
"     9",
"    </a>",
"    ]. In comparison, vagal maneuvers, beta blockers, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    are often ineffective. There is little reported experience with the use of other antiarrhythmic drugs; the class III agents are the most effective among those tested, while class I drugs are rarely of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Catheter ablation has been performed with efficacy rates of 85 to 100 percent in patients with resistant or incessant ILVT or those intolerant of medications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/27,37,72,73,80,83\">",
"     27,37,72,73,80,83",
"    </a>",
"    ]. Selection of ablation target sites focuses on pace mapping techniques",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    activation mapping, with particular attention to the mid-diastolic potential",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    presystolic Purkinje activation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/72,80\">",
"     72,80",
"    </a>",
"    ]. Electroanatomic mapping and identification of the earliest retrograde Purkinje potential can also be used for guiding ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reported series of catheter ablation for ILVT, although small, have demonstrated a high rate of chronic arrhythmia control and relative freedom from procedural complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/72,73,83\">",
"     72,73,83",
"    </a>",
"    ]. In one report, for example, 17 successfully ablated patients were followed for a mean of seven months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/73\">",
"     73",
"    </a>",
"    ]. No patient had a recurrent symptomatic tachyarrhythmia, and in the six who were and underwent repeat electrophysiology study, the tachycardia could not be induced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     MAJOR SOCIETY GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines for the management of ventricular arrhythmias and the prevention of SCD made the following recommendations regarding the management of idiopathic VT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/14/26858/abstract/84\">",
"     84",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is evidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      general agreement supporting RF ablation in patients with symptomatic idiopathic VT that is drug-refractory, or in such patients who are intolerant of drugs or do not desire long-term drug therapy.",
"     </li>",
"     <li>",
"      The weight of evidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      opinion supports the use of beta blockers",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      calcium channel blockers for the treatment of symptomatic idiopathic VT.",
"     </li>",
"     <li>",
"      The weight of evidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      opinion supports the use of class IC antiarrhythmic drugs as an alternative to or in combination with beta blockers",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      calcium channel blockers for the treatment of symptomatic idiopathic VT that arises from the RVOT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/54/13154?source=see_link\">",
"       \"Patient information: Radiofrequency catheter ablation for the heart (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/31/14834?source=see_link\">",
"       \"Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4068780\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant ventricular arrhythmias usually occur in the presence of significant structural heart disease. Less commonly, ventricular tachycardia (VT) and ventricular fibrillation (VF) occur in hearts that appear normal but in fact, contain less visible abnormalities including derangements of cardiac ion channels or structural proteins. Idiopathic VT syndromes, including repetitive monomorphic VT, paroxysmal sustained VT, and idiopathic left ventricular tachycardia, occur in structurally normal hearts and have a more benign prognosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Idiopathic VT syndromes account for approximately 10 percent all patients referred for evaluation of VT, with the mean age of patients with an idiopathic VT being less than that of patients with VT secondary to underlying heart disease. Distinguishing an idiopathic VT syndrome from other monomorphic VT syndromes is important given the far better prognosis, greater array of antiarrhythmic drug options, and amenability to cure with ablation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Idiopathic VT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic evaluation to establish the presence and type of heart disease in patients with sustained VT generally includes various invasive and noninvasive techniques, depending in part upon the clinical history and presentation. These include electrocardiography (ECG), echocardiography, exercise treadmill testing, signal averaged ECG, coronary angiography, endomyocardial biopsy, or magnetic resonance imaging. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43144?source=see_link&amp;anchor=H10017877#H10017877\">",
"       \"Sustained monomorphic ventricular tachycardia: Diagnosis and evaluation\", section on 'Diagnostic evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Repetitive monomorphic VT (RMVT), also called right ventricular outflow tract (RVOT) VT, is a triggered arrhythmia that is characterized by frequent short \"salvos\" of nonsustained VT. The most common symptoms associated with RMVT are palpitations and lightheadedness, typically occurring during or immediately after exercise or emotional stress, although a significant proportion of patients are asymptomatic. Most RMVT episodes have a characteristic ECG appearance with left bundle branch block appearance and an inferior axis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Repetitive monomorphic VT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment decisions for RMVT should consider that many patients are young and otherwise healthy, and as a result, ablative therapy may be preferable to chronic administration of antiarrhythmic drugs. RMVT can be terminated with adenosine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      , and beta blockers, with verapamil and beta blockers also often used as first-line agents to prevent recurrence. While class I and III antiarrhythmic drugs are effective in many patients, catheter ablation is frequently preferred given its high success rate and low rate of associated complications. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment of RMVT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Paroxysmal sustained VT is another clinical syndrome of idiopathic VT that resembles RMVT in many ways. The QRS morphology on ECG is frequently a left bundle branch block pattern with an inferior axis, and patients typically respond to antiarrhythmic agents, particularly adenosine, in a manner similar to patients with RMVT. However, paroxysmal sustained VT is more often symptomatic and less often exercise-provoked than RMVT. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Paroxysmal sustained VT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Idiopathic left ventricular tachycardia (ILVT), also called Belhassen VT or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      -responsive VT, is not usually provoked by exercise and, while frequently associated with symptoms of palpitations and presyncope, is rarely associated with syncope of cardiac arrest. ILVT has a right bundle branch block morphology with a left superior frontal plane axis and a relatively narrow QRS duration (typically 0.12 to 0.14 sec). Verapamil is usually effective in the treatment of ILVT, both for the termination of acute episodes and the prevention of recurrence. Additionally, catheter ablation is highly successful in curing ILVT. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Idiopathic left ventricular tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/1\">",
"      Brooks R, Burgess JH. Idiopathic ventricular tachycardia. A review. Medicine (Baltimore) 1988; 67:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/2\">",
"      Belhassen B, Viskin S. Idiopathic ventricular tachycardia and fibrillation. J Cardiovasc Electrophysiol 1993; 4:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/3\">",
"      FROMENT R, GALLAVARDIN L, CAHEN P. Paroxysmal ventricular tachycardia; a clinical classification. Br Heart J 1953; 15:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/4\">",
"      Rahilly GT, Prystowsky EN, Zipes DP, et al. Clinical and electrophysiologic findings in patients with repetitive monomorphic ventricular tachycardia and otherwise normal electrocardiogram. Am J Cardiol 1982; 50:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/5\">",
"      Buxton AE, Waxman HL, Marchlinski FE, et al. Right ventricular tachycardia: clinical and electrophysiologic characteristics. Circulation 1983; 68:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/6\">",
"      Deal BJ, Miller SM, Scagliotti D, et al. Ventricular tachycardia in a young population without overt heart disease. Circulation 1986; 73:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/7\">",
"      Lemery R, Brugada P, Bella PD, et al. Nonischemic ventricular tachycardia. Clinical course and long-term follow-up in patients without clinically overt heart disease. Circulation 1989; 79:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/8\">",
"      Mont L, Seixas T, Brugada P, et al. The electrocardiographic, clinical, and electrophysiologic spectrum of idiopathic monomorphic ventricular tachycardia. Am Heart J 1992; 124:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/9\">",
"      Ohe T, Shimomura K, Aihara N, et al. Idiopathic sustained left ventricular tachycardia: clinical and electrophysiologic characteristics. Circulation 1988; 77:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/10\">",
"      Kinoshita O, Kamakura S, Ohe T, et al. Frequency analysis of signal-averaged electrocardiogram in patients with right ventricular tachycardia. J Am Coll Cardiol 1992; 20:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/11\">",
"      Yarlagadda RK, Iwai S, Stein KM, et al. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation 2005; 112:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/12\">",
"      Markowitz SM, Litvak BL, Ramirez de Arellano EA, et al. Adenosine-sensitive ventricular tachycardia: right ventricular abnormalities delineated by magnetic resonance imaging. Circulation 1997; 96:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/13\">",
"      Globits S, Kreiner G, Frank H, et al. Significance of morphological abnormalities detected by MRI in patients undergoing successful ablation of right ventricular outflow tract tachycardia. Circulation 1997; 96:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/14\">",
"      Carlson MD, White RD, Trohman RG, et al. Right ventricular outflow tract ventricular tachycardia: detection of previously unrecognized anatomic abnormalities using cine magnetic resonance imaging. J Am Coll Cardiol 1994; 24:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/15\">",
"      Eguchi M, Tsuchihashi K, Nakata T, et al. Right ventricular abnormalities assessed by myocardial single-photon emission computed tomography using technetium-99m sestamibi/tetrofosmin in right ventricle-originated ventricular tachyarrhythmias. J Am Coll Cardiol 2000; 36:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/16\">",
"      Mehta D, McKenna WJ, Ward DE, et al. Significance of signal-averaged electrocardiography in relation to endomyocardial biopsy and ventricular stimulation studies in patients with ventricular tachycardia without clinically apparent heart disease. J Am Coll Cardiol 1989; 14:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/17\">",
"      Oakes DF, Manolis AS, Estes NA 3rd. Limited clinical utility of endomyocardial biopsy in patients presenting with ventricular tachycardia without apparent structural heart disease. Clin Cardiol 1992; 15:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/18\">",
"      Sugrue DD, Holmes DR Jr, Gersh BJ, et al. Cardiac histologic findings in patients with life-threatening ventricular arrhythmias of unknown origin. J Am Coll Cardiol 1984; 4:952.",
"     </a>",
"    </li>",
"    <li>",
"     Fontaine G, Fontaliran F, Lascault G, et al. Arrhythmogenic right ventricular dysplasia. In: Cardiac Electrophysiology: From Cell to Bedside, Zipes DP, Jalife J (Eds), W.B. Saunders, Philadelphia 1995. p.754.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/20\">",
"      Jaoude SA, Leclercq JF, Coumel P. Progressive ECG changes in arrhythmogenic right ventricular disease. Evidence for an evolving disease. Eur Heart J 1996; 17:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/21\">",
"      Hoffmayer KS, Machado ON, Marcus GM, et al. Electrocardiographic comparison of ventricular arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy and right ventricular outflow tract tachycardia. J Am Coll Cardiol 2011; 58:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/22\">",
"      Niroomand F, Carbucicchio C, Tondo C, et al. Electrophysiological characteristics and outcome in patients with idiopathic right ventricular arrhythmia compared with arrhythmogenic right ventricular dysplasia. Heart 2002; 87:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/23\">",
"      Boulos M, Lashevsky I, Gepstein L. Usefulness of electroanatomical mapping to differentiate between right ventricular outflow tract tachycardia and arrhythmogenic right ventricular dysplasia. Am J Cardiol 2005; 95:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/24\">",
"      Corrado D, Basso C, Leoni L, et al. Three-dimensional electroanatomical voltage mapping and histologic evaluation of myocardial substrate in right ventricular outflow tract tachycardia. J Am Coll Cardiol 2008; 51:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/25\">",
"      Callans DJ, Menz V, Schwartzman D, et al. Repetitive monomorphic tachycardia from the left ventricular outflow tract: electrocardiographic patterns consistent with a left ventricular site of origin. J Am Coll Cardiol 1997; 29:1023.",
"     </a>",
"    </li>",
"    <li>",
"     Coumel P, LeClerq JP, Slama R. monomorphic idiopathic ventricular tachycardia. In: Cardiac Electrophysiology and Arrhythmias, Zipes DP, Jalife J (Eds), Grune and Stratton, Orlando 1985. p.455.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/27\">",
"      Coggins DL, Lee RJ, Sweeney J, et al. Radiofrequency catheter ablation as a cure for idiopathic tachycardia of both left and right ventricular origin. J Am Coll Cardiol 1994; 23:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/28\">",
"      Lerman BB, Stein K, Engelstein ED, et al. Mechanism of repetitive monomorphic ventricular tachycardia. Circulation 1995; 92:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/29\">",
"      Kim RJ, Iwai S, Markowitz SM, et al. Clinical and electrophysiological spectrum of idiopathic ventricular outflow tract arrhythmias. J Am Coll Cardiol 2007; 49:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/30\">",
"      Hayashi H, Fujiki A, Tani M, et al. Circadian variation of idiopathic ventricular tachycardia originating from right ventricular outflow tract. Am J Cardiol 1999; 84:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/31\">",
"      Mitrani RD, Klein LS, Miles WM, et al. Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease. J Am Coll Cardiol 1993; 22:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/32\">",
"      Sch&auml;fers M, Lerch H, Wichter T, et al. Cardiac sympathetic innervation in patients with idiopathic right ventricular outflow tract tachycardia. J Am Coll Cardiol 1998; 32:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/33\">",
"      Marchlinski FE, Deely MP, Zado ES. Sex-specific triggers for right ventricular outflow tract tachycardia. Am Heart J 2000; 139:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/34\">",
"      Klein LS, Shih HT, Hackett FK, et al. Radiofrequency catheter ablation of ventricular tachycardia in patients without structural heart disease. Circulation 1992; 85:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/35\">",
"      Calkins H, Kalbfleisch SJ, el-Atassi R, et al. Relation between efficacy of radiofrequency catheter ablation and site of origin of idiopathic ventricular tachycardia. Am J Cardiol 1993; 71:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/36\">",
"      Movsowitz C, Schwartzman D, Callans DJ, et al. Idiopathic right ventricular outflow tract tachycardia: narrowing the anatomic location for successful ablation. Am Heart J 1996; 131:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/37\">",
"      Klein LS, Miles WM. Ablative therapy for ventricular arrhythmias. Prog Cardiovasc Dis 1995; 37:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/38\">",
"      Jadonath RL, Schwartzman DS, Preminger MW, et al. Utility of the 12-lead electrocardiogram in localizing the origin of right ventricular outflow tract tachycardia. Am Heart J 1995; 130:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/39\">",
"      Wilber DJ, Baerman J, Olshansky B, et al. Adenosine-sensitive ventricular tachycardia. Clinical characteristics and response to catheter ablation. Circulation 1993; 87:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/40\">",
"      Timmermans C, Rodriguez LM, Crijns HJ, et al. Idiopathic left bundle-branch block-shaped ventricular tachycardia may originate above the pulmonary valve. Circulation 2003; 108:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/41\">",
"      Sekiguchi Y, Aonuma K, Takahashi A, et al. Electrocardiographic and electrophysiologic characteristics of ventricular tachycardia originating within the pulmonary artery. J Am Coll Cardiol 2005; 45:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/42\">",
"      Kanagaratnam L, Tomassoni G, Schweikert R, et al. Ventricular tachycardias arising from the aortic sinus of valsalva: an under-recognized variant of left outflow tract ventricular tachycardia. J Am Coll Cardiol 2001; 37:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/43\">",
"      Ouyang F, Fotuhi P, Ho SY, et al. Repetitive monomorphic ventricular tachycardia originating from the aortic sinus cusp: electrocardiographic characterization for guiding catheter ablation. J Am Coll Cardiol 2002; 39:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/44\">",
"      Frey B, Kreiner G, Fritsch S, et al. Successful treatment of idiopathic left ventricular outflow tract tachycardia by catheter ablation or minimally invasive surgical cryoablation. Pacing Clin Electrophysiol 2000; 23:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/45\">",
"      Stellbrink C, Diem B, Schauerte P, et al. Transcoronary venous radiofrequency catheter ablation of ventricular tachycardia. J Cardiovasc Electrophysiol 1997; 8:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/46\">",
"      Tada H, Ito S, Naito S, et al. Idiopathic ventricular arrhythmia arising from the mitral annulus: a distinct subgroup of idiopathic ventricular arrhythmias. J Am Coll Cardiol 2005; 45:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/47\">",
"      Yamada T, Murakami Y, Yoshida N, et al. Preferential conduction across the ventricular outflow septum in ventricular arrhythmias originating from the aortic sinus cusp. J Am Coll Cardiol 2007; 50:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/48\">",
"      Yokokawa M, Good E, Desjardins B, et al. Predictors of successful catheter ablation of ventricular arrhythmias arising from the papillary muscles. Heart Rhythm 2010; 7:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/49\">",
"      Gill JS, Prasad K, Blaszyk K, et al. Initiating sequences in exercise induced idiopathic ventricular tachycardia of left bundle branch-like morphology. Pacing Clin Electrophysiol 1998; 21:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/50\">",
"      Dixit S, Gerstenfeld EP, Callans DJ, Marchlinski FE. Electrocardiographic patterns of superior right ventricular outflow tract tachycardias: distinguishing septal and free-wall sites of origin. J Cardiovasc Electrophysiol 2003; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/51\">",
"      Callans DJ, Schwartzman D, Gottlieb CD, Marchlinski FE. Insights into the electrophysiology of ventricular tachycardia gained by the catheter ablation experience: \"learning while burning\". J Cardiovasc Electrophysiol 1994; 5:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/52\">",
"      Marcus FI, Fontaine GH, Guiraudon G, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation 1982; 65:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/53\">",
"      Blomstr&ouml;m-Lundqvist C, Sabel KG, Olsson SB. A long term follow up of 15 patients with arrhythmogenic right ventricular dysplasia. Br Heart J 1987; 58:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/54\">",
"      Ritchie AH, Kerr CR, Qi A, Yeung-Lai-Wah JA. Nonsustained ventricular tachycardia arising from the right ventricular outflow tract. Am J Cardiol 1989; 64:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/55\">",
"      Lerman BB, Belardinelli L, West GA, et al. Adenosine-sensitive ventricular tachycardia: evidence suggesting cyclic AMP-mediated triggered activity. Circulation 1986; 74:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/56\">",
"      Sung RJ, Shapiro WA, Shen EN, et al. Effects of verapamil on ventricular tachycardias possibly caused by reentry, automaticity, and triggered activity. J Clin Invest 1983; 72:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/57\">",
"      Sung RJ, Keung EC, Nguyen NX, Huycke EC. Effects of beta-adrenergic blockade on verapamil-responsive and verapamil-irresponsive sustained ventricular tachycardias. J Clin Invest 1988; 81:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/58\">",
"      Farzaneh-Far A, Lerman BB. Idiopathic ventricular outflow tract tachycardia. Heart 2005; 91:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/59\">",
"      Lerman BB, Dong B, Stein KM, et al. Right ventricular outflow tract tachycardia due to a somatic cell mutation in G protein subunitalphai2. J Clin Invest 1998; 101:2862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/60\">",
"      Viskin S, Rosso R, Rogowski O, Belhassen B. The \"short-coupled\" variant of right ventricular outflow ventricular tachycardia: a not-so-benign form of benign ventricular tachycardia? J Cardiovasc Electrophysiol 2005; 16:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/61\">",
"      Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outflow tract. J Am Coll Cardiol 2005; 46:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/62\">",
"      Viskin S, Antzelevitch C. The cardiologists' worst nightmare sudden death from \"benign\" ventricular arrhythmias. J Am Coll Cardiol 2005; 46:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/63\">",
"      Gill JS, Blaszyk K, Ward DE, Camm AJ. Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. Am Heart J 1993; 126:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/64\">",
"      Rodriguez LM, Smeets JL, Timmermans C, Wellens HJ. Predictors for successful ablation of right- and left-sided idiopathic ventricular tachycardia. Am J Cardiol 1997; 79:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/65\">",
"      Gerstenfeld EP, Dixit S, Callans DJ, et al. Quantitative comparison of spontaneous and paced 12-lead electrocardiogram during right ventricular outflow tract ventricular tachycardia. J Am Coll Cardiol 2003; 41:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/66\">",
"      Schweikert RA, Saliba WI, Tomassoni G, et al. Percutaneous pericardial instrumentation for endo-epicardial mapping of previously failed ablations. Circulation 2003; 108:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/67\">",
"      Chinushi M, Aizawa Y, Takahashi K, et al. Radiofrequency catheter ablation for idiopathic right ventricular tachycardia with special reference to morphological variation and long-term outcome. Heart 1997; 78:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/68\">",
"      Flemming MA, Oral H, Kim MH, et al. Electrocardiographic predictors of successful ablation of tachycardia or bigeminy arising in the right ventricular outflow tract. Am J Cardiol 1999; 84:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/69\">",
"      Lerman BB, Stein KM, Markowitz SM. Idiopathic right ventricular outflow tract tachycardia: a clinical approach. Pacing Clin Electrophysiol 1996; 19:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/70\">",
"      Zipes DP, Foster PR, Troup PJ, Pedersen DH. Atrial induction of ventricular tachycardia: reentry versus triggered automaticity. Am J Cardiol 1979; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/71\">",
"      Belhassen B, Rotmensch HH, Laniado S. Response of recurrent sustained ventricular tachycardia to verapamil. Br Heart J 1981; 46:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/72\">",
"      Nakagawa H, Beckman KJ, McClelland JH, et al. Radiofrequency catheter ablation of idiopathic left ventricular tachycardia guided by a Purkinje potential. Circulation 1993; 88:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/73\">",
"      Wen MS, Yeh SJ, Wang CC, et al. Radiofrequency ablation therapy in idiopathic left ventricular tachycardia with no obvious structural heart disease. Circulation 1994; 89:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/74\">",
"      German LD, Packer DL, Bardy GH, Gallagher JJ. Ventricular tachycardia induced by atrial stimulation in patients without symptomatic cardiac disease. Am J Cardiol 1983; 52:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/75\">",
"      Klein GJ, Millman PJ, Yee R. Recurrent ventricular tachycardia responsive to verapamil. Pacing Clin Electrophysiol 1984; 7:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/76\">",
"      Ward DE, Nathan AW, Camm AJ. Fascicular tachycardia sensitive to calcium antagonists. Eur Heart J 1984; 5:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/77\">",
"      Ouyang F, Cappato R, Ernst S, et al. Electroanatomic substrate of idiopathic left ventricular tachycardia: unidirectional block and macroreentry within the purkinje network. Circulation 2002; 105:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/78\">",
"      Okumura K, Matsuyama K, Miyagi H, et al. Entrainment of idiopathic ventricular tachycardia of left ventricular origin with evidence for reentry with an area of slow conduction and effect of verapamil. Am J Cardiol 1988; 62:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/79\">",
"      Kinoshita O, Kamakura S, Ohe T, et al. Spectral analysis of signal-averaged electrocardiograms in patients with idiopathic ventricular tachycardia of left ventricular origin. Circulation 1992; 85:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/80\">",
"      Nogami A, Naito S, Tada H, et al. Demonstration of diastolic and presystolic Purkinje potentials as critical potentials in a macroreentry circuit of verapamil-sensitive idiopathic left ventricular tachycardia. J Am Coll Cardiol 2000; 36:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/81\">",
"      Nogami A, Naito S, Tada H, et al. Verapamil-sensitive left anterior fascicular ventricular tachycardia: results of radiofrequency ablation in six patients. J Cardiovasc Electrophysiol 1998; 9:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/82\">",
"      Francis J, Venugopal K, Khadar SA, et al. Idiopathic fascicular ventricular tachycardia. Indian Pacing Electrophysiol J 2004; 4:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/83\">",
"      Gupta AK, Kumar AV, Lokhandwala YY, et al. Primary radiofrequency ablation for incessant idiopathic ventricular tachycardia. Pacing Clin Electrophysiol 2002; 25:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/14/26858/abstract/84\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 965 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-37992F4EF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_14_26858=[""].join("\n");
var outline_f26_14_26858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4068780\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IDIOPATHIC VENTRICULAR ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12026071\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Idiopathic VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Other ventricular tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Distinction from ARVC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      REPETITIVE MONOMORPHIC VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Epidemiology and clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Site of origin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Electrocardiographic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - RVOT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - LV outflow tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Electrophysiologic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Malignant variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment of RMVT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29141861\">",
"      Epicardial ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PAROXYSMAL SUSTAINED VT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      IDIOPATHIC LEFT VENTRICULAR TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Site of origin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Electrocardiographic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Electrophysiologic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Treatment of ILVT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      MAJOR SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4068780\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/965\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/965|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/59/1971\" title=\"diagnostic image 1\">",
"      EP study idiopathic LV tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/965|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/45/44767\" title=\"figure 1\">",
"      RVOT nine site mapping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/51/2867\" title=\"figure 2A\">",
"      Noncontact map sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/41/35474\" title=\"figure 2B\">",
"      Noncontact map fascicular tachy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/965|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/27/44476\" title=\"table 1\">",
"      Criteria diagnosis ARVD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2892\" title=\"table 2\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/965|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?31/21/32088\" title=\"waveform 1\">",
"      Repetitive monomorphic VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?9/6/9318\" title=\"waveform 2\">",
"      ECG RMVT from LVOT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?10/2/10280\" title=\"waveform 3\">",
"      ECG Idiopathic left ventricular tachycardia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41637?source=related_link\">",
"      Bundle branch reentrant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=related_link\">",
"      Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=related_link\">",
"      Evaluation of the survivor of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13974?source=related_link\">",
"      Nonsustained VT in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/31/14834?source=related_link\">",
"      Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/54/13154?source=related_link\">",
"      Patient information: Radiofrequency catheter ablation for the heart (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39702?source=related_link\">",
"      Prognosis of nonsustained VT in the presence of structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=related_link\">",
"      Sudden cardiac arrest in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43144?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia: Diagnosis and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_14_26859="Gluten free foods PI";
var content_f26_14_26859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F54353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F54353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Gluten-free foods",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Amaranth",
"       </td>",
"       <td>",
"        Legumes",
"       </td>",
"       <td>",
"        Sorghum (milo)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrowroot",
"       </td>",
"       <td>",
"        Millet",
"       </td>",
"       <td>",
"        Soy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beans/bean flours (garfava, etc)",
"       </td>",
"       <td>",
"        Nuts/nut flours",
"       </td>",
"       <td>",
"        Tapioca, tapioca starch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buckwheat",
"       </td>",
"       <td>",
"        Potato, potato starch, potato flour",
"       </td>",
"       <td>",
"        Teff",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cassava",
"       </td>",
"       <td>",
"        Quinoa",
"       </td>",
"       <td>",
"        Wild rice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corn",
"       </td>",
"       <td>",
"        Rice",
"       </td>",
"       <td>",
"        Yucca",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flax",
"       </td>",
"       <td>",
"        Sago",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Job's tears",
"       </td>",
"       <td>",
"        Seeds",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These foods are usually gluten free, even if they do not say \"gluten free\" on the label. But you can be sure that a food is gluten free if the ingredient label says \"gluten free\" or that it is made in a \"gluten-free facility.\"",
"    <div class=\"footnotes\">",
"     * To be sure that the food is not contaminated with gluten during harvest or processing, the label should say \"gluten free\" or \"processed in a gluten free facility.\"",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dennis M, Case S. Going gluten-free: a primer for clinicians. Pract Gastroenterol 2004; 28:86.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_14_26859=[""].join("\n");
var outline_f26_14_26859=null;
var title_f26_14_26860="LCIS risk factor recurrence";
var content_f26_14_26860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    LCIS as a risk factor for local recurrence in women treated with breast conserving therapy for early breast cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Study, year",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Number of patients w/LCIS within the specimen",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Number of control patients",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Median F/u, mos",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Risk of local failure, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        +LCIS",
"       </td>",
"       <td class=\"subtitle2\">",
"        -LCIS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Sasson, AR; 2001",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        65",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        1209",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        76",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        (5 yr, NSS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        (10 yr, p = .003)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Jolly, S; 2006",
"       </td>",
"       <td rowspan=\"2\">",
"        56",
"       </td>",
"       <td rowspan=\"2\">",
"        551",
"       </td>",
"       <td rowspan=\"2\">",
"        104",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        (10 yr, p = 0.04)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Moran, M; 1998",
"       </td>",
"       <td rowspan=\"2\">",
"        51",
"       </td>",
"       <td rowspan=\"2\">",
"        1045",
"       </td>",
"       <td rowspan=\"2\">",
"        127",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        23",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        (NSS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Abner, AL; 2000",
"       </td>",
"       <td rowspan=\"2\">",
"        137",
"       </td>",
"       <td rowspan=\"2\">",
"        1062",
"       </td>",
"       <td rowspan=\"2\">",
"        161",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        (NSS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Ben-David, M; 2006",
"       </td>",
"       <td rowspan=\"2\">",
"        64",
"       </td>",
"       <td rowspan=\"2\">",
"        121*",
"       </td>",
"       <td rowspan=\"2\">",
"        45",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        (NSS)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NSS: not statistically significant.",
"     <br>",
"      * Matched for histology, stage, age, and date of diagnosis.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_14_26860=[""].join("\n");
var outline_f26_14_26860=null;
var title_f26_14_26861="Loading dose";
var content_f26_14_26861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DRUG%2F52606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DRUG%2F52606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Loading dose",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 42px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_14_26861=[""].join("\n");
var outline_f26_14_26861=null;
var title_f26_14_26862="Breast quadrants";
var content_f26_14_26862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Breast quadrants",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The breasts are divided into four quadrants with nipple as the center.",
"    <div class=\"footnotes\">",
"     UO: upper outer; UI: upper inner; LO: lower outer; LI: lower inner.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_14_26862=[""].join("\n");
var outline_f26_14_26862=null;
var title_f26_14_26863="Pericardial effusion subcostal echocardiogram";
var content_f26_14_26863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/73179/subperef_conv.mp4?title=Pericardial+effusion+subcostal+echocardiogram\" style=\"width:360px;height:272px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pericardial effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 220px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADcAQMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKmtLaa8u4ba2jMlxM6xxoOrMTgD8SaA2Ia9g8IfCqbUPCd/LqZjtLuULJGZE+eELnAzkfeJGR1wB74l+GHgK4QT3N7MEuLiB4fIWXbiM8PuYfTBweM9ea980KykMD2Etwm0k+WWySuCB0B6fNzg+nSnsTufLmr+FY/Dej2ya3ZxF57q6T+0Y3dhtSCMxqg3BeXdvvDJK4yADWj4I8IaPeTulw8WqxXFrdSLjfE9ssXmhJvlfB3Mi8MD94ehJ9l+KPguDWdJnt7e6e3mSMtETJtLMezhSVK8AdP5V8x6raapoE81lcvPAHBRhG7eXIvPHuOT+ZpFGRgkdDRg+lLx3Hp0NGOPfr1oATB9D60EEZyDxwaXA/Lg80YB/Hgc0AJg8cHrijB9D60uP8etGB6e/XtQAmD6UYIHQ0uBjP9aMdu/TqOtACbTnGDnOMUYJHQ0uARx/OjA64469e1ACYOOlGD6H1pcAdf50Y5x+HUdaAEIwcHg0UH2ooASiiigAq7o2m3OsavY6ZYIJLy9njtoULBQzuwVRk8DkiqVbfgjVYNB8aaBq94kr22n6hb3cqxAFykcisQoJAzgHGSKANPxX8PPEfhdbd9Ss4pI57h7NHs7iO5HnocNCfLJ2uP7pwfyNYNxouqW91JbXGm3sVzGoZ4ngdXUE4BIIyBkivW0+NzL8R4dTOmRJ4at9QvbyK0t4limZpw6+e5ywMwVh3x1AxnNWdQ+MVjGNTbS7vW/tL6K+mWV0LaO1kgczLIvKSswUAN824nJ4AoA8kuPDmoRDTViiNzc36s0dtAjtKpVipVl29cg8DNMTw3rjm6CaNqTG0OLjFq58k4zh+Pl455r1HR/ivpkOl6XZ366x540W70u81CAobiOSa483zYiW+fjhslScnn11vAPxY8KeFr4zyP4pvZkvUm+13KRzy3EIgSPaVaULEQVOCu4lQqluKAPDPsF55Cz/AGS48lgCsnlnaQTgYOPXj611J+HGvQ6dp17qEcenx3xuFiju1kjkBhQM25duRkEY9fausg+LUVk/gKKzXUm03Q5Glv7BnCQ3DfaGkUhQxDFQRgsBhhx61up8W/DVtNpKpJ4lv0tX1R5bi+ii81vtUW1AMSnhT15HHI9KAPDTYXnP+iXHEP2g/u2/1X9/p93nr0q1H4e1qURGPSNRcSuI4yts53uV3BRxydvOPTmvY7zx34aTwzJcJb6xNqcnhFfDBkiWJrVWXbtc5YOudvORx2DdafefG+Bo9Xjs7jxBDHONIWzVXCiAW3/HwABJ8oftj738WKSaexdSnKm7SVjwiRHikaORWR1JVlYYII6gimV0PxC1q18R+Ode1mwjljtb+8luY0lUBwrMT8wBIzz2JrnwMnA60yBK6nQNMitLyOa+cEAgxtHkr17H16j2wfwp2+mQRvbMLjz2eMM4WMgQvkgoc9SODxxz9a0LZJvLDRxOXHQrkg8dPfp+FN6CTvqei6L4gmtYEjgkUwAbimNqEAYxwOBz2962JPEl9Kvkxoqqy42RkYA6ZB5x/iPYY80t7hkt5EZfmkGwgYAxjHGce1bVjrH+jG3ZIl6Atkccn0/WkM7HUNdNzLvkkkZmUl8YAzyOfXAIwa43xRGNesvJmfbJAxaKQ4BBPuOx44/L3ia4U3Drb55fcCOgwPpz/wDX/GqV1KsAEiFSGG9s5A3djx79sUAcJf2M+nz+VcxgN1BHIYexqrx9TXU68z3cR8xNsigMnJJBzz9BXNSxNCwDr6EE96AGDH1x710HiDwV4m8OWaXWvaBqWn2zt5YmubdkTd1xkjGcA8exrnvwFfQ3xE+L/hu+8eX0Om6bHqHhm/1OwvNTu2LlryOBIxsWFwuzG0g/3tvXBoA+euMdvzq3Jptymkxai0aCzllaFH8xSxYAEjbnI4PUjFfRGpfEPwZP4m027nvdIu7a2S+8qT+zpmdFkhYRxyK8YUgPtAUBlXnkCuY8I+PvDLWPh+68WraTapHq11cXXl6cuIka2WOGTy1VY2VXAOwemcZ6gHiZxnpx6Z5o4HX9DX0J4S8baDput3l9rnjaDU9Q8i2RLldNmiglQSyF422xeY7KrKRkKp3bSSFGMbxj468Mw6Pf2vhoWEqXfiG8mmiGngM1hIF2hHdMx5wwwpDD2oA8s0vwzq2q2P22ws/MtftUdl5vmoiiZwSqksR1APPT3rKmiaGeSKRVEiMVZd2QCDyM9/zr6Z1H4j+DpZ7eOXxBaXel/wDCR2d7BZJpksaWdlGrAxsvl7TtzggZz1Gcmsvw/wCNfA1r4K1TT7jVYnF5b6irWVxZynbK7OYDEFj2gHKnc7FgcAbQOADwfWtGv9DuIYNVtmt5poI7mNWYHdG65VuD3BBrPwPbjvmu3+Leu6dr+u6Tc6TOLiGDR7K1kbYybZI4grrhgDweM/ka4ft0FADgUxyrE+x/+tRQGAGCik+uT/jRQAyitTw94f1fxJevZ6Bpt1qN0kZlaK2jLsEBALEDtlgPxFTXvhfW9Pm1CHUdOns57BFkuYroCF0ViAp2tgnOR0B9elAGLRVrTLG51TUrTT7CIzXl3MkEMQIBd2IVV545JAqePRdTl1t9Ht7C5n1VJXgNpBGZZC653KFXJJGD09KAM6iiigAooq1LYXkVhBfS2lwllOzJFcNGwjkZcbgrYwSMjIHTNAFWirkOnXU2mXOoRoptLd0jkcyKCGbOPlJyeh6DipdH0bUNaa8XTLZrg2drJez7SBshjGXc5PQD05oAq2l1NaS+ZbSNG/Q46EehHcexq7myv/vBLG6P8QB8l/qOqn8x9Ky6KlxT1NqdeUVyvWPZ/wBafIsXdpPaSBLiMqSMqRyGHqCOCPcVpWMELafCfsx+0+cW+0CXIC4GFKY4IIJ3Z747U/RJbiO1eExxXFvIw/dTAkIw7juD2yP6VowW8NxJv091E7cm3kbnHfaR1/Q/Xuczj8RfsI1daL17Pf5d/wA/IdAqCWX5QkpG47iNr8dvyrX0i6FrOrNKDC2d0MmRuHcA8/07VThjhusrcAwypnIAyFPZsHnrViNDLEiStCzJzhhgk45/z6YNUc7ViXUhaNev9mXCuQcSkbYzxgZHUcnmqIJLSRlim7GXHAXjnj61OsO5QQxkReCwyMjHXPY1I5SC4QHzVIUFd33j6c0CK88rQRrt87YxI4GeOcnjAqBGYwiIBjGfmwSDtHsc/jVtp5bq3jS6uGaJT5gU549Rg/Tnmp76+luwY41EaxDGUACnjoTx78+1AGa6KERmSRUJwoJOfoCetZmsokzkxIyRAZVWbOG9f88VbYmG7kIly6J8zfwjtgfypl4txJ809uIYANxPVjn/APX+tAHOWlrLdXcFtCn76Z1jRTxuZiAP517TB8D4dP8AFGg2Ws+ILWWGfVI9NvoYUKyKxUn93nJZSVKb8DBIOMV5XNC00isXEaDiJ+mCO/6Dmtm7+Jni+e7s57nVImvLO4juI7g2UHmmSP7jPJs3SYz/ABFqAPUNU+HXgu/0dF8PNDHqWr66dGs2d7gpbbCgbAb7zcliW45wvSuE0D4VXWrHTydY0+1ju9UudM3T5UK0CbiR6luir3JHNY1lrviqW1tNl+ba3tb2TV4JGRIytxjc0ikLubhQcDI46VZv/iv4y1CeCW81eGZoJZJ0VrG32b5F2vlPL2tkdQQRnnrzSUk9jSdKcEpSVk9jp5/hFc2sGu6fEBc6hFNpkNvJeQS2jo11M8YAXJVgSoy2WHpzkVBF8Gpb3WdNstI1+0vIbnU59GmuDbvGLe6hj8xl2nllIHDD8hXJX/xF8V30d4lxq7bLpbZXWOGOMKtuzNCIwqjywjMxATbye9WZvij4wl1jTtTfWQLywlkmt3W1hVVkcYeRkCbXdh1ZgWNMzIfG3g2Hw9onh/V7DWrbV9N1gTCKaKCSEo8LBZFKuAcZYYOOfQVyHXrjpWlfa7qN/oemaPd3IfTtNMrWkXlqPLMhBf5gMnJUdSenas3PfIz16UABPPbPWjHOOARx9aOncflR+I446frQAhooJzRQB6P8EPE+i+F9Q8VzeItslte+Hruyit2EmLqVzGRCWjGUDBWG7jHqK7Pxv418H6rJ4ourfUUuoL7RbG202yktJFks2jkQvb7yuMhQx37uc4ye/glFAH154tudO0KC31zVJ4rPR/8AhINIm0y3k05reSytYmDSIq7cuABklNwPYknFcxoHxe0FNd0zUdY1CAzWfia8aOSLTtrJpckJCH5Yxx5hyR9/jpXzVRQB3vhrxHaaN8WrfVtXubXWdMNyY7ydLUpHPC42OyxFVIwpJA2g5Ar0XSfHfgbTvFeo2ljLFDp9npNvp2j6vJaOPnQhpZHVULq0hLDcFJAHoa+faKAPoZviRoFhPdXujzaZFcT+J7S5uXttLYx/Yvs6rOy+ZHlQZAeBhjkkAA0t58QvC9zb6RZw6va2+k6b4ulvHsm058Tae12kiMmIzhVQMSpwxHGDwK8As7uazl8yBsZGGUjKsPQjoRV02sGo/Np6+VddWtSc7v8ArmT1/wB08+malytvsbwoqrH3H73bv6d/Tftfp6rP498N6hD4gOtx2d3CNds5LG1t9PWDzdPjnld1BVFAJV+d5DHPOcca97470Qah4nmm8W22oWN9pGq2unWkOlSQG085FEUJbyx1xtwMqNud3NeAMpViGBBBwQe1NqjA94+IPjTwprnw9k0rw79hUyw2a2mmtZyi5tZkKh9jBPL+Yb8tvJbd0zzXi4tbyzNwrJcW865idOVYYPzKw6j6GtCx0kWs8MlzLBJujSZfKkDYyAcEjowzyvUVsT3Frp1x9pBMsjAvvBLE5659fr+dO1txJ31WxhWVvIsweFcbRvPYYHOa1ru9efGYIy6/KJEUDd9T2ND+IlMUhW2gUhcAqmMZ7j0PfjiqkGsSB1V0j38biycke+OCOlIZ1nhxxM8ZvZEMka4XzOHPpz3FaOr2qojXUKbmJBbbzx64/wA+tc3Fq8TB5L5Y5AgwQCQB/n0q3aa9Yxzx/aIJDg/MYpzHnPqp4yP1rmdCXPzxfyPcpZtSeDeExFLmvrzX1v0e2ttt9hnmXQ8vMcbDGEAHXPrjv7VYwLm48u5t5jMcEiEhlHp1HHToPWtqO/0C4guAukqPlAjbzMY47gHvUdrqnh+1C/aknkjbO5Q2Ap9ieff1rpPDOTkRIpN6yKQh4U8k9PXj1/wpJ2cxoPMy7tnrgAZ7AV0VrqmhtqIj0/S2vRuI8thtAHoWHUc9/wBaRvEVpcTNaweG4bYwvmURZLHttLHgAepwDScktGzWNGpJKUYtp6bdexixRMtsPLQ+cTwxPC++f72PpirVr4d1O9t7i6S2vDDxuYx9skctjA/PPNdBc+LNNsLdGstK0+KThUWNFckjnJY8Z47Zrn9d8a61qdun2m9bysYWBW+VV9u35YqeZv4UaewjD+LK3ktX/kvm7+Qh8MxO4+1SRoAfnJbJx7fhUd+NHt4DHa+VFcKCschUOyn15B/x9COow991fToFkeNV4IdhkZ/x9BSzWc0UTLu5ZsYCjOOwx/U96OW/xB9YUP4St57v7+nySM6zadtWuPtcjvN9nuNxckk/uXwaye3J98CujsUaW+lE5G4W0+GxnaDG9c9LG0TskgIYH0pr4v68xTblRi3veX5RGk85zz9OKOnQ5P0oz+f0o4z1OPp2qjnDvjI9M0fjz1zSDHf+VHGP/rUALnGcH9KBjpnge3NGf8elHHqcZ9O1ACq5AxhfxUGimgken5UUAJRRRQAUUUUAFFFFABSg4OR1pKkkieNI2dSqyLvQn+IZIz+YI/CgDQF3DfqE1I7JwMLdqMn6OP4h79frWpH4de1t4pp1EryhsDjYMHggg85HPIFRaHBaR2sUtxZNLc+YSHL5TaQABsx1yGOc+nHetiTxCSrWl/CGGcrhiDt9QfX3qbcvwnSqsa+lbR9/8+/rv67GJJnzvJYvAw5yzZBI9fQ/59qz3kI3GKZgwPAFXry2WdJbq0mM8A5Ynh4+2WHp/tDg+xqnBHCV/wBIfBHDjGT35H/1qaaexlUpSpu0v+H9BkBeU+UG3vz1PysPQVLbRzeajoScHqpHPfPP+f62Izbwyr5LgunQ9cehx6c+tR/a084yKFzncRjkHp3/AM/zpmZNJbxRyZmEijGXVhj8R+lOWNwcwP5kagc5IP8Ah+dMk1KSNioeNPl4IQA49PaoPtmYTkxGQ4HXgigCyGc3u5ZipXG3+E0yWWaW4BPmYH8Z6AfXH49Krx3rnZv2tHxkMfu/n+P+etiTWJ8eXCI406YwuPz7/rQB22hXujafBstpjJI2N8nlsNx9OQPyrH8S61BeTy29rE0qkDduBGGHoOhPSuYe+kcFXjB34BwOePb+laOjWQuZn+1CZI/4VReT9fxrCGHjGfPe7PYxOdV6+GWEUYxguiTX6v5lKDzEJ8wbZF+75i4xz6e1WtOC3GoJDdSZhBy4+7n245HepZoI7ScKY2lBORGWx06Z/wDrn61raLbwz6hGTEkbscIWGcH2963PHLwtII1C2iImCQpK9umOeevHaqN+fJk8mZyoxt/dRgAewGP8OtdaNEhWSSRZZA4XK7zyx7EDqB/Osq90y2+yYSYy7Rk7TgA++f8APFAHOWW/7dJcOxEQgmwOmcRt+f41g3wa4uvlH7xuh7KPUmuqSKCN5cTM0qwS9Tzny2zj8/8AOK5Q/Ir+ZIFVuMAcnH1/z0qV8T/ruby/gR9ZflEouvlyMpJ4OMj0poPHceuKe5BXIyD65/SiON5JFjjjkZnIAVeS2TwB+NUYDAeDz7+1JnjipbiKS3nlhnUiSJyjjOcMOMfoajyevOeuc96ADPGBn6UZHHXHp7UZIHGQP85oz7ken0oAUbSPmZs/TP8AWigbDyzMD7L/APXooAZRRRQAUUUUAFFFSQRPPNHFCpeSRgqqOpJOAKNw2I66FteFz4Wh0a4skka3naeGddieWGVFYEBQSSEXJLds1nRS3+harL5TSWt/bGSF8YyhwUYfqRUEZC8nhlPJ/wAe/tT2JtzGjp941rbyRkeZG5Bxnue+fX/PpVSaf7SPMc5IOMNjn2J4pGBlj34PPJCjr+FJauFZvMHmqR1B59On+f8AFFFi0M1rIs8MhDgkqexz1/8Ar/TFXGih1eMGExwXo6KvCP8AQ/wn26elZcoQEKrHrn3B6fj+ta2l2kJb96skLoP9Yq8fiO4qXG+q3NqdZxXJJXj2/wAuz/p3RUnsrlFH2mLEikggjDfn3PNPEBmJiZSpj5LE4I454rtLa3TUrYfa9rGM8OrfPj+o5pl5B5SJbzJyD+7kK7gR7dB+HH0oUujKnRVuem7x/Fev+e3z0Ob0vTI5JEjmmkjX14I9s8H3/l9OmtfBbCQSpFFPavgBlfGB9Ac1o2V9Bo1gROsLq3HzRZHPqDyOlcvfeIJIcm2EokycOGwBz06+9UYNNOzLUnhW0WZgsyAg4YA7dn1yKv6Z4OtrmMKYzPFkjzY8MT/gPwrCh8VyeXsuLdZj0xsHB/HvzVmy8Twq6ZuZ4iPvLk/kCOfwoEbEGgWAuwEjeONGMYk2DIPHbr+la9v4Re5JMbXCbQdkkin5s9On4YqSDxnpSabHANPSWXJJnwxb/wBCx0rqtL1W61fTi1lfiztFT5gIPJ49mAJNAHGt8PZLaOWbUpZLeJl/1r5Qkc4wp/zzVO6QaJpZS2EL25PyTMo8xiDx64HvT/E2vSeZJFDercRxN94jccjocsPauRudSu7uQLcb5pM4jGAcD0H8qAL/APbjQSuThpX6nqR9PX/PSqH9qXAhMYZcd9p3HtnmqEwlfOV2JjDogxx6ZA9f896mUtHGjoscTdUZxlh7hf8A9X+IBpaY7zaiA0RULFIo3Y+Y7G4x1PFUZrdJ3bfsYqTkc4/z/nrT9KvE+2SRqGJSGUszN85PlseKybi5Z38wfKhJ4B5Pp+H+eKlfE/67m8v4EfWX5RKl2qRXB2nJXjA5GPf0qTStUvdJ1ODUbGYJeRhikhjWTGVIJwwI7nnt1HQGopJvmZcAZP8AF2460lvA1xIsMXmF5MBVAyWPbj0/z2qjAjuZ5LmTzJFjBA6RxqigfRQBUWCeuc+/6Vt6joTWNuGmYGU8kKcgD0+tYhG0kMORweaADOTyevU9aM8cnNHtxgd6DkdcjIoAUKCM7lX25opODySc+wooAbRRRQAUUUtACVLND5UjJvSQjuhyKdKkKW8LRzeZI4PmJsI8sg8c98jn8ai/QY5we1MQA4OeD2x609tshJ6EZP1puCuCep5GackbOpZRuVeTx0/+tSGXLZpdmxcFS2OeMH0z2qrPlZDkBXI+b/61XLXYLcqyneRjjkn2I71RYkyZUncD8pB5oAnfEkCnDYACh+g/E1u2NwiQpHKrFvbpVOyGY2MWVmChjgZDD3HQ/X9Krz3jAKyMEOeig7c/57YoA6Z7mHZujfy50GcNnn+v4foauaLrtp9qIvLmONAvGWOGPbII4PvxXErcSTKcFie5Veg/WoHJRiwIIY45HH+P+frUThzxcWdOExLwtaNaKu10ex6b4pgF9pn2mwMU+w/NsYHK9yD049/6V5tdLiYhsl+fmx2+mcd6jhne3ZnileOQ9GRzk+xIIp0EqRksTGz+jRg5qaNN048rdzpzTG08dW9vGHLJ763Tff8AzIy5XaR1Gck9+h44pyuwJbb8oHTt9Dnr9KsLLFMGaSBd3fa2Bj6E9KiiAeY7kLkHohwB2xitTzS9BfXM5jjL7EUgYXj6fXtXVPdT22kuTMhUrgRPIT+lc5YxQRDzJ4fLwcoHb+Q/z3qHUr9Lgr5MaiMHmTG0n9KAGyXMbjzDtBJHEZCj/wCtSxX1vbxPsBed+MA4UfjUNhYS6vdTR2wIZImkAOTkDkD8cis3v835deKV1exbpzjBTa0d7fLc04LuSVSjyoFznA+RR+X9KsR/vJDK3l4TjO7BP+f6VlRRsVOAFGM5P+elEUfzAqrFcgljxn6f5/KmQb1lGv2l5ZRvc285UAcD902ePSsaIsszMqAsed2Pu/59a63wxpkt/FJcrswqyRAOSMEoQOMdOR/9eud1vTp9OvGgu3jaVvm/dHcMHtjHbr/hWUakXNxT1PQq4OvDCQrSi1Ft6+qVvyZmSFWPXOTkknrzXW+CrN4Ve6MajAPztwB+NczaRK9yoIIAOQp6/ifwrvtO0+OG1UanMViVd4tYRgn03N0UY7deO1annmbr7x3KMts/nyliWcDO32Hv/L3rkLqPygFbG8DkZzj2/wA+ldJqd4glKxgRRE4AQEZ+nqPc1g3sah8jC85weeP6mgCiOSBjPoMdaTnB9PXFPZG5yOnHBzj3pn04oADyck5NFODMoxhfxUUUAMooooAKtA2g09gVn+3+aNrbh5fl4ORjGd2duDnHXjvSWtwLeO4UwQymaPy8yKSY/mU7l54bjH0JqKNSTxkqO/1p7C3EAORjj0IpXQpg44PIz/KrqQMF+dMIVHzBffrx/P8AnS+UpDRk/e54/i9/rSGU4zlNuNwz938Oo/wrZ8ORRT3AR5BHIfuMRgMMd/8AP+NZUtuY3JXmPOQy9vatLRwkcqMWyoYfKQdpP9DQBva94emsrVZpYdkcigq+Pl+voQa46WIqxDbi3Qk8/Q17RbasZPDQttsN1CRzBMOR9D6/rXkmp2xjmmNupADn5BycdsjuaAK0Fy8bo4J445b+tJJ88zMg6nv1/wATz3psY+fdg44+ZTn8+P8APFW444s7S3BHI2j8/TPT8vrQBS81hIJFb5gOWHGf8/59KeLg7CrEOp+8CP60yWMK5CsCnTjr/n/CmBBwCreu4UANJJPB56Ad6B14zwc4FTrbtKwVWTdjoB/hV+20qWVmXDgD+HacH8cUAZkUjhuGYknpnr+dSxJ5jAPwB3Cgcfh/9et/+x9PhVTJfTRSKM7Cg5/zx1qjd6lcQMY7eRBEpyD5Yyf50AVZkjSPy1mLnvhMY/UCq6jCbgpLdOmVPoP6f5zTpbrzWRpVDEDkHgGpzOJIwioluO7+Z/n/ACaAOr+GcBaa/unGGwqDjHXk/wAhWP4y0sQa1I1myvFL+8KqQdjE8j255/Gs23IWWLyZXmlRg4VVwOCD1p+qWrWer3JGVQSsVIx03HGB9MfrXOqbVZzvue1Ux8KmWRwvs9YPe/e72t8t+hSa2ljwWQLn7qsM55H51p2v7s+ZcRs/fDcAd8Y/P1qhJLLJKuME+nU5+tTymV03SxSbR0A+Vf17f410HinS+CdVKa1NbTBYo7hSUHbcuTn8s/lXMa1dvqGr3V0ScM5K57L/AAj8hSWuyImVm2t2C5z/APWpVBuXCxIxP97j/wDVWSpJTc+531MwqVMJDBvaLb+//LX7zR0MxRzq8jYYL/dy5x2X0/lWzqk8xTMibUUjEQ4C+7E9/rWdpNnepLm3jLOBgADLN+Pp/wDXro38MX08O67DYA4ijH8z2/z+OpwHHXUrztGiEs2fmYfyGail091/eXDqikcFhn8h3/H17dte+smhn22sfCcbh2Prmsu8ZldI2kDY6c5C56/U0AUbpgI9sS4jzuJPc+571U5GN27/AOtV25OPmcA/3Qx5PuapuSx3t+XagBlFFFACxo8sixxqzyMQqqoyST0AFWLW5ubCWVrd2ikaN4XwOdrAqynPqCR+NO0i6jsdTtbua3W5jgkWQws5QPg5xleR+HNafinWbLW9Ta8s9Ig0lZB+8it3ZkZvUA/d9wOKadtUJq+jMLpkZ/AVas2/fR8E7SDx25/+v0qBiUJ5x6YGMg96mtGUXMZztIIIPHNIZ2+mWqCN2MLSWx+ZwOdn+2nqD3H0rM1vQ/sh86ACSE/MCBnj1H6cV1/h+7tnhjV2EU2Btbt061Hq/kTF0VPs9yoydv3JRn7w9D19vYUAecfaDvClcH7hZujD3H589vetLTcIrb09iDz+R7j9frUN3C6XcjYyCT84HT6jvU62Uk4Bj+RyMHyz8rfh2+lAHT6Pd2yMLd4vOjbseGUdsHuPaofEfh6S8ctZq6uOdr4Bfntz/wDX4qbw7p8EiIk12bWccASDMbeh9R/Kr+qre2KmK7k8y3PzRzRHcFH+FAHnRWaykZbiLByVYOcg9vT8P/rVYWG2uIi1pJsmGCYnGQOOxzWnqzRzyAF1Bxy2Sfx5rLmtBCscoktyc8snH5igCtJbSyoPKtypXk46LTYg9vNt8wRk8DPKk+me3FaasFkGJ2iH94A8fiD/AIfzqpeS4cn7YJ8DJJOCQfpQBHNdK7DzeJRjDKMnP/16kOrMYgkimQJ3Y8fkR+n1qrHGLpl2qxIHp+uB/npUV3beS46HPHByfy49aAJLq88wt0AJwwAxz64NUwQFBVm3DkcdP1pApzgDnoMdzV210m9uVzHC2zGdxIAoAo4IAIyAe/rR0HIxWqNDu1GZAF7YAz/k0QaZhmErYI45GaAMokjIYsPX+laGtZe6il6+dBE347AD+oNR3FpiYpGVduflj7VdvIHWy02SRfmVGidW9nLf+zCpe6Z0U9aU49rP8bfqUbciNgXIDdQ7c4+lNnmM8mNzyKD0A6j/ADil/eh+I1BOcHHQevH86mjtJ53Ko7Mx/hGf0qjnK42qQHOM/wAK/L09ea6jSNOe8CLar5S5A3kHcTx0X9Mn9K6bQfCC2dtBcavEAXAcRgjew9P/AK31rau9TEMoisLWCxhj4DuBuPvjjjH/AOugDV0WzttH0sCd4oSqjeB80hPUAn19ugrA1nVbq/Q28ExELNnK4Axyccdf0HvWFrN9LcuxDz3DMeNq8d+T/hWPDOEfyjMVi/id23nPoAP8/wBQCfV45HQW9qcovMkpbAz7H8P881z9xby206LsVpW6Zyc+3+f/AK1dHcPGGWODdlv+Wh5OPX2/Cs/UIkj2w2qiW5/jJySvuff/AOvQBj3iRxLt3mSY/ePv9fX/APXWeMltxY46E44x7f4Vau4mU7ZHCqOvf/PaqjZOQAxx3JzQAm5Ty4Zm7nd/9ailAYj5WAHYFxRQAwY70o65HHv6UdBz19DQc55zkcHNACqcY54B/wAmr9pGjqGHC919CO9Z56DjjsTT45XjI2Nj86ANn7bcWXCNui67euB9PzpZtRa5kUea4x0z1Xv19KyHuGYDLEL0x1xTAzjg9Oh59+lAGtPNIkvmx7lkHJYHIatjSXW5jBBCXAHH8JbH+f8AGuZjnduAMZ6/XtV6C6uLcg7Ayeg45/GgD0LS7lFjH9o2AkKcbwoO4fh+NbVlLZag6/Y5LdADho5G2rn15/8ArVwOn6lNcMBDJKjjoFbk/h6/Sry30u/Y6p557FB831B60Ae3/wDCufD9/pa3DvHp1313Od0THvyOR39fxrwvx54dXRrpkMUbJnCyROHVuf8A9XFdBa+KLuzsXjhkaBWADqjHY31HX9K5nWrxLyImZVjYZ2vCw2n3GPw4oA5i1G1l2hSmeBvx/I+tTzm3CbjbzI2McgMD36jmopwu4eWwds8Zj2nnjqKrSSPnBDRsRj5ScH+dABJcIP8AUs6A+qg5quZXkIDEP7EUOq5+TIBOMMOfwo8tmAwoGevY/wA/cUANyGwoUA5GMCr1rFeSqvkgkZ6Fuffqf/r1HZXE0MoxIUJ4BIyPz/OtXzjcR/PPbup4O7P+FAFqC1kjVTcNcjIxiNQwPt1pl2EZcRLLLIOvnY4/AZpkU8FtH8i28jdMn5cfnTLi7VgAJkgB+9tYZP4c/SgCg3n5ZVLqR1CkKP0FWvJM2iqJG3eTcdiT95P/ALCqsxaWULDNJM2Opzz3yePpV6xtvLsL+NmV22pIsYzn5WC8kezfzqZ9zow+spR7p/gr/mirAqRuok81s8BV/h/ye3/669C8NaNDAglS3it8HJZwST+HJ/lXEaRZXU95DGkW0PwFXk/1/wAP6euw2EFpYLHPPDbEc43b5OB7ZAP5VRzlHXPEChRbadBNcXBGNx+UfX/PFcrfOWUvMRJMeoi6A+5PXv8A5NLesltPKLeUTmRicMCoJ9Tzz1/zzWLNLdO5Zn2sPX5UUf1/CgB9xcyoh87IHOEBwAD6nv8AhWUsiy3JZWVCOBgZx9KuTSpIHVnTavBYckn/AD/+qswrGhLuwQMeOc8dqAJ7mZxuZJT7u7cf/Xp1pc7leOyCqwGWlbgAev8A9aqEyJswznJ9T07UqAhBHyVHzbWGB+X+NAEN2QzgK7Sgcb+Ru+g/z0qBiVQKSMHPT/Pt+lT3R5CjB7bR07cYqqxzye9ACHr2ooPXniigBRzwMnnj1NJjp0Hal6jjJI7egpPXFAATntzSk9j+Q6UHPHX2z6UenOOKAA9+nHenxuAckMV6HHHFMHJB4z6dBQeepz+NAF+BVkUFSQR1YdvqOuPbpWhDI627RzRLKgJwV4I/+v8AlWCrFSCGwQcjHB/OrlpfeU4aRdw6EjrQBp2iGWf7nyrnbx82Px61auXfeizr50QPXcQ6/T/CorS6gy3lyK0Z+co6YI9/8/8A16Wa7V3DCRnUcEdePT1/XigDasmt1QvNLKYjxll3Y9v/ANVVNatrcx+ZZTRy7uojJP6H/H+VUrfUoIZCBvjBIBKnIP4c/rViS5hmjfyPs8mehA2H8OaAMS6EqRDdJEyjoRjKn+lV4pcsBIM544Yf5/z+TpyrzMxbjI5KhsY/pUDb4zgMPUcbf5/hQBJPDIW5UEdOX7n/ACKRAsgyyOyjjIIJ/wA/570x53IAbY35f0/z/Kk8mQkthV75OBj8qALMMUHnFXWXGMbFODirk0VqpDmK5K+oG4f5/wA/XNiYL97enYcjj86tzXTSbl8yUY6gsCPTt/j+tADJj5eScqOedoB/Xn/Gqe2NjuVmwOuQPTpz+NOCRu/LBevYnPr61IkcWSNyNGO/P/1vagCSyMxG6EEDOSc8n8cV1vhjQ76/ncyRMkDIUMjZUDPQn15x3qv4S0j7VehkMR4/v7Rx25r0DUGn0yzjSSWJIyygqH6889CB+hqZ/CzfDNKtC+10aGg6Dp+jZSGN726/iETKBn/eOareLIY47VpLjyLcgZ8uOQuQR0yxO39O1c/Z6m8MbRzX7qQSNsSDcfx/z3rM1JraUMZJZZCOm58kfieP5/4UYtNOzOWk1OUylVfPJwwxyO1XoJiyh5xx69SffJ6d+9Y9x9nNw5jWQdRnbn9ai+0SGRFALHgj5s/5PtQI3L2OzWINtUORkHJ5/wARXPTkKS0YbGOWP+PatFll2ebdSLDGegfksf61l3MyvKfKJKgYG7j8frQAtv8AuvmwF7bj396bcXBbIGQc8jGMGoZJGlOXzx6dqaMcZx+NAB1HX/61HsRjj0o5xznpQOnA+tACH2ooPU5xn2ooAXr3yfc0dcenQZPSjr6dPpR1/HrxQAHHbHPP0o98d+oHSk454FKfU5yeee9ACdsf0pemOmOoFB+73I7fWjt1785oAAcDIOCD+NHY4GRj8qMksM8t24zmgYxz0z170AAbaRgnjOMHFXbPUJLWXcyrKD94NzmqRzg884557UEccc47+3vQB00epaVcbTJG1u3ORIvmL+BHzD8qc8FjOpELdRwUbcM/Tr6d/wA+tcv1zkk85Jx+tKCVOR1GOhxQBtEmGYLIFkUdPMjII/z0qO6ltyu1reWPd3D5X17/AP66p299cw7QrF1HZhuHNWjq6yKRcWVu4PUp8p/CgBttp6vz5yBTxhxzn8qW4s4IOWlVj/D5TjOcUn26Ff8AVeaq9NrncP8AGrEF7ZEMJ4lGeCwU/kRQBnrDGULRTjb6N/n61bsrd51CiR0HYBOn6+lJcfZHlxFcsiE4w0Zb+lMmkhjwYbqJiRziAjP50Aab6epUIxeUjGTsAPH1/wA/pVqDRmkJPlNjqQ5BH498VY+Gui3njHxjp2g2N1Zx3d2ZNkkysFXZGznOFPZT+NSaHpuseMGlg0K0nvRCF81gqxom44UFjgAk8AZyewoAn0+L7FKrSvEqgYLROGI4707VtTtGjKLNKx9d3H5Z611Hhn4W6pqHh2TUrtpraZdRGlx2s0LFjNuCkvz8ihjgnBOQeOlcj4m0fWdI8YyeFP7PRtV+0fZ4liKnzyW2qUOM4btnB55GaAEudTt4LyVVYKXPmfKvJDDd/UfpWbcXUGGZ3lIHOCAD/P8ApRB4T8WXtxaCHSb15bmWaCHIzuaHiQc9AncnAHtViL4Z+NbvUrixi0G9lubcRPINysqJLny23Z2lW2nDA44NKKskjStP2lSU11bZz8s9uzlnLuSflQD/ACD/APWqtHdmEk26hTzgnqPf3rrm+FnipPDur6vLYeUmmXf2O5t5CRMr7dxYDoVAxznnIwDUdx8N/EGnW2pS6/puoaYbS0e6RXtc+YEdUOTkbVy4+bmmZnHSyPK5d2ZmPfPbpTO3t646V6H4W+EniTWNV0y21C0k0q1vldluZlDFcQPMu6MMGXcIzjOK56LwR4km8Ntr0ekXDaUkZmM428xg7S4XO4qDwWAx70Ac6OeTzj3oOec5yOOe1HUE449ugowOKADocrn1+lJkelKTnOeSec0Z9OO4APSgBKKD7UUAL1GSaTPPPPFLnuTyPXmtLUdMNjpun3W4lrpGYjH3eePzBBpNpNIiU4xaT6/8OZp+uT0o6dOnUEiuy+D9pa3/AMStDtr63gurV5XDxTRh1YeWx5U8H8fSub11Ei1vUY4lREW4kVVUYCgMcAelMsokckYGfb+dA6449Bnijjj0z171p6LpZ1L7ZhseTAZRgdT2FJtRV2ROcaceaWxmDHrx34pPrilz6cGjODleO4OeRTLEx06UuRnJwe9HTtzQBkgDJz0470AIO3Q98UDngck1pa7pr6VfLC0hcsiybuhyevf1BrO6jAzj0pJqSuiYTjUipR2YEDBIzjNB4PQA9MUH8COlHbgexNMoM9+hI7UY4PBGP51pwaZ5ugXOpBjthmVCnscd/wDgQrM6Y46deetJST2IjOM7pdNAxweP1o46j9eaBx6ZHP1o/Ue1Ms6r4XeLj4E8daZ4iNl9u+w+b/o3m+Vv3xPH97a2Mb89D0xXVeHfifpHhv8AtOz0Twzc2ui6hHCZYP7UDzpPGzkSJK0RABDgFSh6ZBGa820i1W91O0tmJCyyBWIHIGef0qK8hNtdzwMQ7RSMhb1wcZpXV7E865uTrueh6l8UZLyzijXTX86LxGPEAmuLsyszCNEEbfKCf9Xktx16Cub8XeJotX8b3fiXR7ObSpri6N7sNz5xScvvZg21eNx4GOPU1zR6nnPbNHXnseuB05plHseo/HO5ufG9trkGg29tYJZXFnNpqTkiQ3Ds88ivt+Vmcg9D071leKPil/bOga5pUemXaR6jBZW8c11qAnaAW0ssnGI0BB83AAC4x3zXmPPfOff0oIx16+mKAPV/EXxbt/ED+KPtvh9gmr30GowiO+2m2lii8sZPl/vFI5xhfqazdS+Jf23xB461NtKKf8JPam28v7Rk2wLo27Oz5/uYx8vX2rzo88flzRjrwCPX0oA9dh+Llh/wmsHi+bwq7+I2Ui6mXUmWKbNs8B2R+WdmdytyW+7gYzmqqfFyR/A0OhXOm3AuoNLk0qO6trwQo8LBgBJH5ZLY3Ho6g9xXlh55OSSepo9wcfjQAHrk8k+9J0GAf/r0vQZH6igehxj+VAAc8gkdfyo5OT19eKBj29KTg9etAA2c8jBHFFOCgjl1Hsc/4UUAKoYkBQxbOFAPOeK6XXZI5tM+yxOHe1MChR1/1RDEevzAZr6t/wCGVfBHbVfEg7f8fMH/AMZpP+GVfA+T/wATTxIP+3iD/wCM1Eo3afYxqUueSlfY+Z/gsrw/FDQpJsoizOWduMfu35zXOa9ZTya7qRERVGupMFsDPzHnnHHvX13/AMMq+B8f8hTxJ/4EQf8Axmgfsq+B+f8AiaeJP/AiD/4zVamjUujPjT7HccHy2BPoOg6c4rc8OyHT4Jxdp5YuZYosSfL8vzbjzzgZFfV5/ZV8D/8AQU8Sf+BEH/xmg/sq+CD11XxL/wCBEH/xmplHmVmZ1aTqx5JPQ+NLq2kjuZYwjsqMVGBxjNPisZXAM2y3jxnzJTtGMdh1P4Amvsn/AIZW8EdtU8SD6XMH/wAZpB+yr4IH/MV8Sf8AgRB/8ZqtS7Sta58d/YLfBxq1l6H5Zv8A43Ultpzm+txG8VxCzrmWPO0DIznIBX8QK+wP+GVfBH/QV8Sf+BEH/wAZpf8AhlXwR31TxJ/4EQf/ABmlZ9yXCVtJfl+lj5K8TzLqZt72Il3YyRsF5wA+QfbIb9KyIbOedwqxlT0LONir7kngfjX2Wf2VfBB66r4l/wDAmD/4zR/wyp4H/wCgr4k/8CIP/jNEY8qshU6XsockXsfHIs4QcSX1tHIeqje4X2yqkH8Cf54c2nBlJtry1uWHJjjLqxHtvUZ+gyfavsU/sq+CDn/iaeJOef8Aj4g/+M0f8Mq+CO2qeJP/AAIg/wDjNFn3K5Jb835f1+J8q2JWHQWsGZVuLqKSYq5H3gy7Rz3Ozp71zPkygjEbgjvtNfZ4/ZV8ED/mK+JP/AiD/wCM0o/ZV8EDH/E08Scc/wDHxB/8ZpRjy38yaVH2bk093c+Ok05kRWubq3tQeVEjFmz7qoJH4gUh09QCFv7MyZwFDsNw9ckYH0JB9q+xf+GVfBH/AEFPEg/7eIP/AIzSj9lXwPx/xNPEhx/08Qf/ABmnZ9yuWf8AN+B8j6NFLp97PPKE2wwSFJFYFGbbxhhwevb+lV9ciL6pLLbqWjmCygryCWUFuR7kjFfX4/ZV8EAjGq+JQR3+0Qf/ABmj/hlXwRg/8TTxJ/4EQf8Axmko+9zEKk1U9o3rax8aw2U8oywEMY6yS/KoGfXv9Bk0l5BFCV8m7huc5z5auNoHTO5R+melfZZ/ZV8D/wDQU8Sf+BEH/wAZoP7Kvgg9dV8SH3+0wf8AxmqszWzvds+LMdj27ijkZGQMfrX2p/wyr4HzxqniT/wIg/8AjNIP2VfBH/QV8SEen2mD/wCM0yj4s9uADzQce4/CvtQfsq+B+P8AiaeJP/AiD/4zSD9lXwPn/kKeJD/28Qf/ABmgD4s7ds0ckcn8TX2n/wAMq+CMY/tXxJ/4EQf/ABmj/hlTwP8A9BTxJ/4EQf8AxmgD4sPQ8UZ+oU/nivtP/hlTwP8A9BXxJ/4EQf8Axmj/AIZV8EDpqviX/wACIP8A4zQB8WHpznPv6UH9Ow9K+0/+GVfA+P8AkKeJP/AiD/4zR/wyr4Iz/wAhXxL/AOBMH/xmgD4sKsSTy3v60V9p/wDDKngf/oK+JP8AwIg/+M0UAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subcostal view from a 2-D echocardiogram shows a large serofibrinous pericardial effusion. Echos are seen within the effusion, suggesting the presence of fibrous stands.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_14_26863=[""].join("\n");
var outline_f26_14_26863=null;
